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From the Editors
As this issue of Medicine +Health went to press, a number of important changes 
took place at the GW Medical Center.
Last May, the University’s Board of Trustees asked the administration to con-
duct a strategic review of the Medical Center’s vision, strategy, and structural re-
lationship with the GW Hospital and the GW Medical Faculty Associates. Given 
that the existing relationship between the three separate entities has been in place 
for more than 10 years; there are new changes and challenges in the nation’s 
health care system; and there is greater competition for research funds, the Board 
hopes that the multi-phase review, being conducted by an experienced consulting 
firm, will continue to raise the Medical Center’s academic stature and position it 
for the greatest level of success in the decades ahead.
As part of this process, John “Skip” Williams, M.D. ’79, Ed.D. ’96, M.P.H., 
senior vice provost and vice president for Health Affairs, decided to take a year-
long sabbatical. In addition, Jim Scott, M.D., recently announced that he will 
step down from his position as dean of the School of Medicine and Health Sci-
ences (SMHS) and return to his full-time faculty position. We extend our deepest 
gratitude to both Williams and Scott for their guidance, leadership, and generous 
support for this magazine.
Until a permanent dean is appointed, University Provost Steven Lerman, 
Ph.D., appointed Jeffrey Akman, M.D. ’81, the Leon M. Yochelson Professor and 
chair of the Department of Psychiatry and Behavioral Sciences, as interim dean of 
SMHS and vice provost for Health Affairs. Akman also will assume the roles and 
responsibilities of the vice president for Health Affairs. In addition, the provost 
appointed Vincent Chiappinelli, Ph.D., the Ralph E. Loewy Professor and chair 
of the Department of Pharmacology and Physiology, as interim associate dean and 
associate vice provost for Health Affairs. More can be read about the Medical 
Center review and interim leadership at www.gwumc.edu. 
In the meantime, Lynn Goldman, M.D., M.P.H., the new dean of the School 
of Public Health and Heath Services, is moving the school forward with an am-
bitious agenda (see page 16). Jean Johnson, Ph.D., F.A.A.N., has also assumed 
her new role as the founding dean of GW’s School of Nursing (see page 7), with 
significant plans to expand our nursing programs.
Finally, as you’ll read elsewhere in Medicine + Health, an extraodinary amount 
of new research is taking place across the campus, from an NIH-sponsored center 
for HIV/AIDS investigations, to advances in our understanding of cardiac prob-
lems and cancer cells, to the search for a treatment for children who suffer from 
a deadly genetic disease.
We hope you will find these stories as interesting as we do and trust that you’ll 
contact us with your views and ideas.
Left: Jeffrey Akman, M.D. ’81 
Right: Vincent Chiappinelli, Ph.D. 
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FROM THE CENTER
Redefining Normal  
RISK FOR MISCARRIAGE GREATER IN WOMEN WITH  
SUBCLINICAL THYROID DISEASE  
Throughout his 20-year career studying thyroid disease and pregnancy, Alex 
Stagnaro-Green, M.D., M.H.P.E., senior associate dean for Medical Education 
at the School of Medicine and Health Sciences, has found that “normal” is not 
so easy to define. Although the normal level of thyroid hormone in non-pregnant 
women is already a relatively narrow range, Stagnaro-Green recently confirmed 
that these numbers might need to be tightened even further during pregnancy. 
“In the last two decades, we have learned that an underactive thyroid, or 
hypothyroidism, is associated with an increased risk of miscarriage, an increased 
risk for preterm delivery, and a decreased IQ in the unborn child,” he explains. 
“Now, the question is: Does an even slightly lower thyroid function still put a 
woman and her developing child at risk?” 
To find out, Stagnaro-Green and his colleagues from the University of Illinois-
Chicago and two hospitals in Italy measured the thyroid stimulating hormone 
(TSH) level in more than 4,000 pregnant women. TSH is a hormone that is 
released when the thyroid’s function becomes too low. Because recent studies 
suggested that the normal TSH may be no higher than 2.5 milli-international units 
per liter (mIU/L) in pregnant women — as opposed to the accepted 5.0 mIU/L 
upper limit for non-pregnant women — Stagnaro-Green and his colleagues com-
pared the pregnancy outcomes in women who had TSH levels below 2.5 mIU/L 
with those whose TSH was between 2.5 and 5.0 mIU/L. 
Although the team found no differences in the preterm delivery rate, the dif-
ference in miscarriage rates was startling: It was 3.6 percent in the women with a 
TSH of less than 2.5 mIU/L versus 6.1 percent in the others. 
“This study is the first to demonstrate that the upper half of the accepted  
normal range on thyroid function tests is associated with a 69 percent increase in 
miscarriage,” says Stagnaro-Green. “This leads us to think that all pregnant women 
should be screened for thyroid function and treated for any abnormalities.” n
Bridging Science 
and Medicine
CHILDREN’S NATIONAL  
MEDICAL CENTER AND GW 
PARTNER ON $20-MILLION 
AWARD TO CONVERT BASIC 
SCIENCE TO CLINICAL CARE  
In recent years, significant insights 
have advanced our understanding 
of such fundamental human health 
issues as the human genome, cancer 
cell behavior, and brain function. But, 
as many researchers know, the chal-
lenge lies in translating those insights 
into clinical applications that improve 
patient health. 
Increasing the momentum of, and 
nationwide capacity for, this crucial 
translational research is the focus of 
a prestigious, nationwide awards pro-
gram funded by the National Institutes 
of Health. And as a recent recipient 
of the program’s five-year, $20-mil-
lion Clinical and Translational Sci-
ence Award (CTSA), a collaboration 
between the School of Medicine and 
Health Sciences, the School of Public 
Health and Health Services, and 
partner institution Children’s National 
Medical Center will be a key part of 
that effort. 
“Our vision for the CTSA is the  
same as other CTSA institutions in  
the country,” says Jill Joseph, M.D., 
Ph.D., principal investigator of the 
CTSA and director of the Clinical and 
Translational Science Institute at 
Children’s National. “It is to do every-
thing we can to ensure that there is that 
movement from basic discovery to 
improvements in human health.”
The GW/Children’s National part-
nership joins the CTSA coalition of 55 
leading health institutions nationwide, 
but is the first award recipient to ©
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focus specifically on how scientific breakthroughs from the labora-
tory bench can be brought more quickly and efficiently to children’s 
health care. 
The partnership will explore avenues for translational research 
among childhood diseases including cancer, birth defects, develop-
mental disabilities, and asthma; diseases that persist into adulthood, 
most notably congenital heart disease, cystic fibrosis, and muscular 
dystrophy; and diseases of adulthood that begin in childhood, such 
as hypertension, type 2 diabetes, and obesity. 
“We’ve been talking about everything,” explains Joseph, “from 
methods to improve vaccinations for diseases of poverty, to interven-
tion programs that help terminally ill adolescents communicate their 
wishes regarding their end-of-life care, to creating opportunities to 
develop the high-performance computing capabilities necessary to 
support the advanced imaging needs of modern health care.”
According to co-principal investigator Peter Hotez, M.D., Ph.D., 
GW Distinguished Research Professor and chair of the Department 
of Microbiology, Immunology, and Tropical Medicine, “There have 
been a lot of genomics and proteomic activities at both institutions, 
and this award will help move those spheres of research into clini-
cally applied methods and technologies.”
Chief among the goals of the grant will be the health needs of the 
District of Columbia population. “We want to create strong linkages with 
the Washington, D.C., community to better understand and address 
their needs,” says Joseph. “Childhood asthma, for example, is excep-
tionally common in the District. Families in the area, and across the 
country, have already benefited from what we’ve learned about better 
clinical treatments. . . . We look forward to even greater breakthroughs 
bolstered by potential collaborations with consortium institutions.”
The grant also is expected to expand the pool of young investiga-
tors engaged in translational research. “Expanding our translational 
research and development activities within the different components 
at both GW and Children’s National will provide new education 
opportunities for young investigators,” says Hotez. 
Those education opportunities will include the region’s first Master 
of Science degree in Clinical and Translational Research, as well as a 
Graduate Certificate in Clinical and Translational Research, based in 
the School of Medicine and Health Sciences.
Joseph Bocchino, Ed.D., M.B.A., chair of the Department of Clinical 
Research and Leadership, will serve as the director of the new pro-
grams, which are geared toward Ph.D.s, M.D.s, and others working in 
basic or clinical research who want to broaden their skills. “Traditional 
research programs train people in a deep, but narrow scope of inter-
est,” he explains. The strategy of these new programs is to help people 
develop a broader base of experience across the continuum, from basic 
science, to clinical research, to matters of health policy. 
GW and Children’s National hope that this multifaceted approach 
will put a new focus on pediatric translational research not only dur-
ing the grant period, but long into the future. n	
When the AIDS epidemic first emerged in the 
early 1980s, the median length of survival for an 
individual diagnosed with the disease was just 26 
weeks, recalled Anthony S. Fauci, M.D., director 
of the National Institute of Allergy and Infectious 
Diseases. But today, according to Fauci, a newly 
infected 20-year-old might live an additional 52 
years, thanks to the development of more than 30 
anti-retroviral drugs. “There are very few examples 
in biomedical research and the application of thera-
peutics that are as impressive as this,” he said.
Fauci made these and other compelling 
observations about the state of global infectious 
diseases at an event to celebrate the 10th anni-
versary of the School of Medicine and Health 
Sciences’ Department of Microbiology, Immunol-
ogy, and Tropical Medicine.
During his lecture, Fauci called upon the global 
health care community to mobilize and use the 
same research model it employed against AIDS 
to combat the world’s three other most devastat-
ing and widespread diseases that affect millions 
of people: tuberculosis, malaria, and neglected 
tropical diseases. “We live in a global commu-
nity,” he said, and the health of that community 
“is critical to everything from our security to our 
economy.” n
Battling Global 
Infectious Diseases
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FROM THE CENTER
Sidawy Named New 
Chair of Surgery
Following a nationwide search for a new chair of the De-
partment of Surgery, the School of Medicine and Health 
Sciences found the person for whom it was looking close 
to home with the appointment of vascular surgeon Anton 
N. Sidawy, M.D., M.P.H., to the position. Sidawy, who has 
held academic appointments in GW’s Department of Sur-
gery, joins the school after having served as the chief of 
surgical services at the Veterans Affairs Medical Center in 
Washington, D.C., since 1996. 
Sidawy brings to the GW Medical Center a distinguished 
career. He completed a fellowship in vascular surgery at 
the former Boston University Hospital (now Boston Medical 
Center). His work has been published in more than 100 peer-
reviewed articles, and he has authored or co-authored more 
than 40 chapters and abstracts. He holds or has held leader-
ship positions in local, regional, and national organizations, 
including serving as the current president of the Society 
for Vascular Surgery and on the Board of Governors of the 
American College of Surgeons from 2001 to 2007. Currently, 
Sidawy serves as the editor-in-chief of the Journal of Vascu-
lar Surgery, the premier journal in the specialty, and on the 
editorial boards of Annals of Vascular Surgery, Vascular, and 
Perspectives in Vascular Surgery and Endovascular Therapy.
“I have been associated academically with GW for 25 
years, and I have always been impressed with the high qual-
ity of surgical work being performed at this institution,” says 
Sidawy. “I am very fortunate to be given the opportunity to 
lead this department to the next level.” n
Breathing Easier
Susan Ceryak Receives R21 Grant to Uncover  
Mysteries of Respiratory Carcinogen
It is a pervasive environmental and occupational hazard 
used in numerous industrial processes and commonly 
found in dyes, paints, car exhaust, and cigarette smoke. 
Erin Brockovich made it famous, and the Environmental 
Protection Agency (EPA) condemns it. Numerous in vitro 
studies have made clear that hexavalent chromium (Cr (VI)) 
is a compound that, when inhaled, initiates tissue inflam-
mation, cell death, and eventually lung cancer. But no one 
has quite yet figured out how. 
Through a two-year, $275,000 R21 grant from the 
National Institutes of Health, a team of researchers led by 
Susan Ceryak, Ph.D., associate research professor in the 
Department of Pharmacology and Physiology, will study 
exactly what happens from the time a cell is exposed to  
Cr (VI) particulates to the time a tumor develops.
The GW team, which includes Stephanie Constant, 
Ph.D.; Steven Patierno, Ph.D.; and Arnold Schwartz, M.D., 
Ph.D., will use a new mouse model that displays chronic 
lung tissue inflammatory responses and a form of Cr (VI) 
that is environmentally and occupationally relevant, mimick-
ing human exposure to particulate chromate compounds 
more closely than ever before. As a result, they hope to 
show the steps of chromate-induced carcinogenesis and 
to confirm the link between tissue inflammation and carci-
nogenesis. 
The investigators also expect their research to result 
in key pharmacological benefits by identifying molecular 
targets for potential interventional and preventive therapy. 
“We may be studying one very specific compound and 
one very specific type of cancer,” says Ceryak, “but I have 
always been confident that the results of our work will have 
much broader implications.” n
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GW Doctor Receives Top 
Psychiatry Honor 
Amir Afkhami, M.D. ’03, Ph.D., has witnessed the devasta-
tion of war in regions of Iraq and Afghanistan. He has seen 
cities destroyed, citizens and humanitarian workers injured, 
and helicopters downed on his very same flight path. 
But most concerning to Afkhami, who is assistant profes-
sor of Psychiatry and Behavioral Sciences in the School 
of Medicine and Health Sciences (SMHS) and of Global 
Health in the School of Public Health and Health Services, 
isn’t anything visible. For him, the mental wreckage of  
warzones is more than just collateral damage. 
“Very few other issues can be addressed from a medi-
cal perspective for a population if you do not first address 
the underlying psychological and psychiatric impact of 
conflict,” he believes.
This philosophy — and the reputable career he has 
made from it — recently earned him the recognition of 
“Psychiatrist of the Year” by the Washington Psychiatric 
Society (WPS). 
“Dr. Afkhami had the profound insight that stabilization 
of health and especially mental health services is a crucial 
element of rebuilding societies that have been severely 
damaged, by war and terrorism,” said Robert W. Keisling, 
former president of WPS. “For his creativity, clinical 
wisdom, and commitment to fostering psychiatric services  
as an instrument of peace, the WPS is proud to honor  
Dr. Amir Afkhami.”
As an advisor to the U.S. Department of State, the U.S. 
Army, and the Iraqi Ministry of Health, Afkhami guides 
efforts to rebuild the mental health infrastructure in Iraq 
and Afghanistan — regions whose mental health systems 
are deeply antiquated, if not absent altogether. Working 
with clerics and faith healers in Iraq, Afkhami has helped 
to shift the nation’s view of psychiatric disorders from mor-
ally wrong to medically significant. His mantras of cultural 
competency and respect have shaped a generation of 
military personnel, whom he briefs prior to deployment.  
Afkhami’s reputation as a global policy authority — he 
was instrumental in the Iraqi Health Initiative and influential 
in the U.S. State Department’s targeted development plans 
for Iraq, which included mental health thanks to his memo 
— earned him the recent election to the prestigious Coun-
cil on Foreign Relations, where his presence as a doctor is 
extremely rare.
“Psychiatry and mental health have, in general, been 
neglected in global health,” Afkhami explained. “I hope 
to use my presence on the Council to raise awareness on 
ways to enhance psychiatric care, expand our knowledge 
on the extent of the problem globally, and to suggest ways 
in which we can bring about measurable change.”
Afkhami earned his M.D. at SMHS, while simultaneously 
pursuing a Ph.D. in the History of Medicine in the Middle 
East at Yale University. “GW put me in a unique position 
to bring together these two seemingly disparate fields,” he 
says. “Had GW not been supportive, I wouldn’t be where I 
am today.” n
	
An Environment for Science
Perry Appointed Chair of Environmental and  
Occupational Health at SPHHS
For nearly two decades, Melissa J. Perry, Sc.D., M.H.S., 
has championed the cause of health and safety for  
farmers and agricultural workers, publishing extensively 
her research on environmental and occupational hazards, 
such as excess rates of cancer in those exposed to toxic 
chemicals. As the new professor and chair of the Depart-
ment of Environmental and Occupational Health at the 
School of Public Health and Health Services, she will 
bring that zeal for environmental science research to the 
school’s leadership team, beginning in January 2011. 
“Dr. Perry has been a leader in researching the health 
effects of agricultural work and exposure to pesticides, 
including cutting-edge research on endocrine effects of 
pesticide exposures on women’s hormonal cycles and 
male fertility,” says Lynn Goldman, M.D., M.P.H., dean of 
the School of Public Health and Health Services. 
Perry brings a distinguished list of credentials to her  
new position at GW. She earned a Sc.D. from the Johns 
Hopkins University and has served on the faculty of the Har-
vard School of Public Health for more than a decade, most 
recently as associate professor of Occupational Epidemiol-
ogy in the Department of Environmental Health. nPH
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FROM THE CENTER
When tourists visiting Washington, 
D.C., lose their way, they consult a 
map or a friendly local. But when new 
cancer patients get lost within the 
labyrinth of health care systems, treat-
ment options, and appointments, their 
solution is not so obvious. Without 
a map or a guide, navigating cancer 
care, as well as life after successful 
treatment, can become nearly as  
traumatic as the cancer itself. 
But two major grants promise  
to help the GW Cancer Institute 
(GWCI) create a road map to guide 
patients along both the local and 
national routes from diagnosis to 
post-cancer care.
The American Cancer Society 
(ACS) and GWCI recently received a 
$4.25-million grant from the Centers 
for Disease Control and Prevention 
(CDC) to establish a National Can-
cer Survivorship Resource Center, 
allowing ACS and GWCI to collabora-
tively guide national progress toward 
improved health outcomes for cancer 
survivors. The partners will develop a 
strategic plan for enhancing nation-
wide surveillance of cancer survivors.
“Collaboration is critical to address 
the needs of more than 12 million 
cancer survivors in the United States,” 
says Steven Patierno, Ph.D., executive 
director of GWCI. “The GW Cancer 
Institute and the American Cancer 
Society are taking a major step toward 
developing and implementing a cancer 
survivorship strategy that will improve 
cancer survivor care and quality of life 
through the new center.”
Over the next five years, GWCI and 
ACS will assess current survivorship 
initiatives, identify gaps in cancer  
survivorship, and support collabo-
rations with cancer coalitions and 
national, state, and community-based 
organizations to set the course for 
cancer care and survivorship pro-
grams in the future.
On the local level, GWCI is already 
one step ahead. Having recently 
received a $2.4-million grant from the 
D.C. Cancer Consortium, the insti-
tute will establish and coordinate the 
Citywide Patient Navigation Network 
(CPNN). Through a system of patient 
navigators and community sites, the 
network will serve as a seamless and 
cohesive framework for cancer care 
coordination across the entire city.
“This grant allows us to both deepen 
and widen citywide efforts in cancer 
care coordination,” says Patierno, 
noting that CPNN will be an expansion 
of GWCI’s existing navigation network 
— which resulted from the institute’s 
five-year Patient Navigation Research 
Program demonstrating the effective-
ness of patient navigation. 
Through CPNN, D.C. residents will 
receive assisted access to appro-
priate screening services. Should a 
suspicious result be found or a cancer 
diagnosis be made, the network will 
further guide patients through timely 
and coordinated treatment following 
the standard of care. Finally, naviga-
tors will monitor patients throughout 
the cancer continuum, connect-
ing them with appropriate support 
services all the way into the post-
treatment survivorship period. This 
comprehensive aid is anticipated to 
improve health outcomes, particularly 
among populations suffering from 
cancer care disparities. n
Paving the Way for a Smooth 
Continuum of Care
Survivorship and Patient Navigation Grants Help GW Cancer Institute 
Plot the Course from Diagnosis to Life After Cancer Treatment
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A report by Avi Dor, Ph.D., profes-
sor of Health Policy in the School of 
Public Health and Health Services, 
calculated the startlingly high indi-
vidual costs of obesity to Americans. 
The report, “A Heavy Burden: The 
Individual Costs of Being Overweight 
and Obese in the United States,” 
measures indirect costs such as lost 
productivity, and direct costs includ-
ing obesity-related medical expen-
ditures, to estimate the price tag of 
obesity at the individual level.
Dor and co-authors Christine 
Ferguson, J.D., Casey Langwith, and 
Ellen Tan concluded that the yearly 
individual cost of being obese is 
$4,879 and $2,646 for women and 
men, respectively, and adding the 
value of lost life to these annual costs 
produces even more dramatic results: 
$8,365 and $6,518 annually for women 
and men, respectively. The findings 
reveal that the areas where costs are 
highest for women are job-related 
costs, including lost wages, absen-
teeism, and disability.
Dor notes that these estimates, 
while staggering, may even understate 
the total individual costs of obesity. 
“Existing literature provides informa-
tion on health- and work-related costs, 
but with the exception of fuel costs, no 
published academic research offers 
insight into consumer-related costs, 
such as clothing, air travel, automobile 
size, or furniture,” he says. “Anecdotal 
evidence suggests that these costs 
could be significant.” n
Research  
Finds Extra 
Pounds Lighten 
the Wallet 
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In	the	coming	years,	the	U.S.	is	expected	to	face	a	national	
shortage	of	nurses	twice	as	large	as	any	experienced	since	
the	mid-1960s.	Many	experts	believe	the	need	for	more	
nurses	will	intensify	as	baby	boomers	enter	their	golden	
years,	and	as	health	care	reform	allows	millions	of	addi-
tional	Americans	to	access	primary	care	services.	Moreover,	
many	women	and	men	in	the	current	nursing	workforce	are	
also	reaching	retirement	age.		
GW,	which	has	educated	nurses	for	more	than	a	century,	
recently	took	a	significant	step	to	help	address	this	serious	
issue	in	the	nation’s	health	care	system.	At	its	May	2010	
meeting,	the	GW	Board	of	Trustees	voted	to	move	the	former	
Department	of	Nursing	Education	out	of	the	School	of	
Medicine	and	Health	Sciences	and	establish	a	new	School	of	
Nursing	(SON).		
“We	are	thrilled	to	launch	the	School	of	Nursing,	which	
will	give	our	programs	the	national	recognition	they	need	and	
deserve	to	reach	their	full	potential,”	says	Dean	Jean	John-
son,	Ph.D.,	F.A.A.N.,	who	was	selected	as	one	of	the	school’s	
founding	administrators,	along	with	Ellen	Dawson,	Ph.D.,	
A.N.P.,	a	new	senior	associate	dean	at	the	school.	The	act	of	
establishing	a	new	school	“demonstrates	that	the	University	
believes	nursing	education	is	important	to	its	future.	This	is	a	
big	step	forward	for	us,	one	that	brings	with	it	the	potential	
to	recruit	more	outstanding	faculty	and	students,	and	improve	
our	rankings,”	Johnson	explains.
Nursing	education	at	GW	reached	this	point,	says	Johnson,	
largely	thanks	to	the	team	she	built	after	her	leave	of	absence	
in	2002,	when	she	served	as	a	Robert	Wood	Johnson	Founda-
tion	Scholar-in-Residence.	The	team,	including	Dawson,	who	
was	serving	as	chair	of	the	Department	of	Nursing	Education,	
recruited	a	highly	motivated	faculty	that	created	outstanding	
education	programs,	including	the	Master	of	Science	in	Nurs-
ing	(M.S.N.)	degree,	the	Doctor	of	Nursing	Practice	(D.N.P.)	
program,	and	the	second	degree	Bachelor	of	Science	in	Nurs-
ing	(B.S.N.)	—	a	program	whose	relevance	was	reflected	in	a	
fivefold	increase	in	applications	in	its	first	year	alone.	All	three	
nursing	programs	have	been	accredited	for	the	maximum	term	
by	the	Commission	on	Collegiate	Nursing	Education.		
Most	recently,	the	Department	of	Nursing	Education	
established	a	learning	laboratory	for	policy	activism	through	a	
Robert	Wood	Johnson	Foundation	grant	to	improve	the	quality	
of	health	care.	In	addition,	Johnson	and	Dawson	have	fostered	
a	nationally	recognized	partnership	with	the	National	Commit-
tee	for	Quality	Assurance,	making	GW’s	M.S.N.	program	the	
only	one	in	the	country	with	a	focus	on	quality	improvement.
“In	a	short	period	of	time	we’ve	generated	a	sizable	
amount	of	research	grant	activity,”	notes	Johnson.	“That’s	
important	in	academic	health.	We	don’t	just	educate,	we	also	
add	new	knowledge.”
For	Johnson	and	Dawson,	the	development	of	SON	is	
a	green	light	for	continued	growth.	Chief	among	their	priori-
ties	are	expanding	the	B.S.N.	and	the	Nurse	Practitioner	
programs,	which	will	help	increase	the	nursing	workforce.	
“As	the	founding	dean	of	the	school,	I	hold	a	lot	of	responsi-
bility,”	Johnson	admits.	“But,”	she	quickly	adds,	“everyone	in	
the	school	shares	that	sense	of	responsibility;	it’s	a	big	part	of	
why	we’ve	been	so	successful.”	n
Establishing a Higher Level of Care
GW MED ICAL  CENTER  LAUNCHES  SCHOOL  OF  NURS ING
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The District of Columbia 
Developmental Center for AIDS Research 
A Center 
for the Epidemic
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By Thomas Kohout   Photography by Mary F. Calvert
itting in his office along Pennsylvania Avenue, Alan E. Green-
berg, M.D. ’82, M.P.H., radiates an air of excitement. Green-
berg, professor and chair of the Department of Epidemiology 
and Biostatistics at the School of Public Health and Health 
Services (SPHHS), recently learned that the National Institutes of Health 
(NIH) has selected the group he leads — a partnership of Washington, D.C., 
institutions — to establish the District of Columbia De-
velopmental Center for AIDS Research (D.C. D-CFAR). 
This designation marks the University’s first-ever NIH 
Center grant and instantly vaults his consortium into a 
network of the 21 most elite HIV/AIDS research organi-
zations in the United States. 
News of the grant could not have come sooner. By 
all accounts, the nation’s capital is in the grip of an epi-
demic. Washington, D.C. has an HIV/AIDS prevalence 
of more than three percent among adults, the highest 
infection rate in the country and more than three times 
the Centers for Disease Control and Prevention’s thresh-
old for a severe epidemic. African-American residents 
account for 57 percent of D.C.’s population, but they 
total 81 percent of all new HIV cases and approximately 
86 percent of people living with AIDS. The challenges 
confronting African-American women in the District 
are still more daunting: They represent 90 percent of all 
new female HIV cases and 93 percent of women living 
with the disease.
 NIH founded the Center for Aids Research 
(CFAR) program in 1988 with the goal of providing 
administrative and shared research support to aca-
demic institutions that conduct the best investigations 
involving HIV/AIDS. NIH currently supports 17 full 
CFARs and four developmental centers. The program 
emphasizes interdisciplinary collaboration, especially 
between basic, clinical, and behavioral investigators, 
to achieve translational research in which findings 
from the laboratory are brought to the clinic and com-
munity and vice versa. It also stresses creating oppor-
tunities for early stage and minority investigators and 
research on prevention and behavioral change. 
The five-year D-CFAR designation, with funding 
totaling $3.75 million, brings together GW’s SPHHS, 
School of Medicine and Health Sciences (SMHS), and 
Columbian College of Arts and Sciences, Children’s Na-
tional Medical Center, Georgetown University, Howard 
University, and the Veterans Affairs Medical Center 
(VA). “What the D.C. D-CFAR can do in Washing-
ton, D.C., is create a community of scientists who can 
conduct the highest level of research on this disease,” 
explains Greenberg.
Many would say that Greenberg had excellent 
preparation to make the D.C. D-CFAR a success. 
He earned his medical degree from GW’s School of 
Medicine and Health Sciences in 1982 and his M.P.H. 
from the Harvard School of Public Health in 1999, and 
then served for two decades as a U.S. Public Health 
Service Commissioned Corps Officer at the Centers for 
Disease Control and Prevention (CDC). He ultimately 
rose to head the center’s HIV Epidemiology Branch, 
where he supervised research studies in 28 states and 
nine countries in Africa and Asia. Greenberg also has 
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“This is an important chance  for 
all of us to have a major impact on an 
epidemic that is harming so 
many people in our nation’s capital.” 
co-authored more than 100 articles and book chapters 
on the epidemiology and prevention of HIV/AIDS and 
related diseases in the U.S. and Africa. Among his nu-
merous other appointments, he is a principal investiga-
tor of the Public Health-Academic Partnership with the 
D.C. Department of Health; clinical research site leader 
for the D.C. site of the NIH-funded HIV Prevention 
Trials Network; chair of the Global Work Group on the 
Advisory Committee to the director at the CDC; and 
a voluntary HIV/AIDS physician at the D.C. Veterans 
Affairs Medical Center.
With GW serving as the administrative home of the 
D.C. D-CFAR and Greenberg as the principal investiga-
tor, this partnership will provide the infrastructure to 
facilitate collaboration, data sharing, and enhanced re-
search opportunities among the entities. The center will 
be led by an executive committee and five coordinating 
bodies, or “cores” — administrative; developmental; 
clinical; basic science; and behavioral science, preven-
tion, and biostatistics.
“Our main deficiency in HIV/AIDS research in 
Washington is in basic science. That’s the area we’re 
focusing on,” explains Michael Bukrinsky, M.D., 
Ph.D., professor and vice chair for research at SMHS’ 
Department of Microbiology, Immunology, and Tropi-
cal Medicine, director of the developmental core, and 
interim director of the basic science core. The region has 
a talented pool of clinical and public health researchers, 
Bukrinsky explains, but “there are very few HIV/AIDS 
researchers doing basic science work. This is an area we 
need to develop in order to support the other research 
studies. The only way to accomplish that is to attract 
new people, especially young investigators.”
Earning such a prestigious research classification 
was no small task for Greenberg and his colleagues. 
Successful applicants need to have a significant level  
of funded research already in place, as well as a dem-
onstrated commitment to HIV/AIDS care. To meet that 
standard, Greenberg and D.C. D-CFAR co-director 
Gary Simon, M.D., Ph.D., who is also the director of 
the Division of Infectious Diseases and vice chair of the 
Department of Medicine at SMHS, decided to pool re-
sources from across Washington. “Our vision was that 
by getting people together from institutions throughout 
the city, we could assemble a successful D-CFAR,” 
explains Greenberg. At the time the application process 
began, GW might not have met those criteria on its 
own. By creating a proposal that included all the major 
HIV/AIDS research institutions in the city, however, the 
application exceeded all benchmarks. 
“The HIV/AIDS community in the nation’s capital 
is allied and deeply committed,” says Greenberg. “The 
idea is to transfer this positive energy into increasing the 
quantity and quality of research.”
Each of the institutions in the D.C. D-CFAR has 
a robust HIV/AIDS care and treatment program and 
boasts active, federally funded researchers. Together, 
they bring strengths to the center that are simultane-
ously diverse and complementary. The VA and Children’s 
National have distinct patient populations. Children’s 
National is actively involved in adolescent and pedi-
atric HIV trials networks. Fred Gordin, M.D., chief 
of Infectious Diseases at the VA and professor of 
Medicine at GW, leads HIV/tuberculosis studies and 
the local component of the Community Programs 
for Clinical Research on AIDS, a community-based 
clinical trials network. Georgetown University is home 
to the Women’s Interagency HIV Study, and Howard 
University is a critical partner for its own HIV/AIDS 
research initiatives and for the recruitment and train-
ing of minority scientists. GW, in addition to having 
strong epidemiology, surveillance, behavioral, and 
biostatistics resources, is home to Simon and his team’s 
clinical, patient-based work that uses antiretrovirals 
and antiretroviral regimens. 
Greenberg notes that the developmental designation 
is a one-time, nonrenewable probationary step. After 
that five-year period is over, centers may apply for full 
CFAR status. The new D.C. D-CFAR, he says, will 
be judged on the collective success of the participat-
ing institutions in conducting outstanding HIV/AIDS 
research that will influence the field and, they hope, lead 
to better prevention and treatment in the future. “If the 
research and financial contributions are strong, and we 
do the things necessary to demonstrate that we took 
this opportunity and made the most of it, I’m confident 
that we can make the transition to a full CFAR,” says 
Greenberg. “This is something we can all be proud of 
because it gives us the chance to have a major impact 
on an epidemic that is harming so many people in our 
nation’s capital.”  n
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A Smart Investment
COMMUNITY HEALTH CENTERS OFFER ANSWERS TO  
CONCERNS SPARKED BY NEW HEALTH CARE LAW
eighton Ku, Ph.D., M.P.H., professor and director 
of the Center for Health Policy Research in the 
Department of Health Policy at the School of Public 
Health and Health Services, doesn’t try to quell the 
political and ideological discord ignited by the passage of 
health care reform. “Unfortunately, empirical information 
does very little when people have strong ideological beliefs,” 
he maintains. 
But above the din, two key questions have emerged that 
Ku feels quite comfortable answering: Will the United States 
have the primary care capacity to serve the newly insured? 
And can we contain the growing costs of health care? These 
issues, he and his colleagues have found, are largely addressed 
within the health care bill itself. 
“The $11 billion in additional grant money for non-profit 
community health centers included in the health care reform 
bill will both bolster the capacity of the nation’s primary care 
system and reduce the long-term growth in health care costs,” 
the team concluded in a report released June 30, 2010, by 
the Geiger Gibson/RCHN Community Health Foundation 
Research Collaborative at GW’s School of Public Health and 
Health Services. 
According to the report, the expansion of community 
health centers (local, non-profit, community-governed health 
care providers that offer comprehensive primary and preven-
tive care in medically underserved communities) will increase 
the number of patients receiving primary care by at least 18 
million by the end of the decade, effectively doubling the 
number of people served. 
Not only will the law create more sites and bigger venues, 
the report says, but it also will shift the patient demographic 
from uninsured to insured. Because 32 million more people 
are expected to be insured by 2019, health centers — which 
accept patients regardless of ability to pay — will absorb 
fewer uncompensated health care costs, thus increasing their 
capacity to serve. “These two forces, additional grant funding 
on one hand, more insurance coverage on the other, act syner-
gistically to enable health centers to grow very rapidly,” says 
Ku, who is an expert in health care financing and budgets. 
Community health centers are lauded for their team-based 
approach to care. As opposed to private practices, the centers 
thrive on a diversity of professions, with nurse practitioners, 
physician assistants, and community health workers all 
helping to deliver care. “This is a more efficient way to deal 
with the scarcity of primary care physicians, without risking 
quality,” says Ku. “This is the kind of team-based care that 
primary care needs to adopt in the future.”
In addition to helping millions of people receive primary 
care, the expansion of community health centers will save 
the country billions of dollars. According to the analysis, the 
investment will reduce total national medical costs by more 
than $180 billion over the next 10 years, including more 
than $50 billion in federal Medicaid expenditures, and more 
than $30 billion in state Medicaid expenditures. Even after 
controlling for differences including insurance status, health, 
gender, and age, the annual savings from community health 
centers totaled as much as $1,100 per person. 
Although the exact savings are subject to variability, the 
findings are supported by prior research demonstrating that 
community health centers improve the quality of care and 
reduce the need for more expensive treatment. Even more 
important, the predictions are likely underestimates. If future 
appropriations are approved, medical costs may be reduced 
by as much as $300 billion over the next 10 years. 
“We have been running community health centers since the 
1960s,” says Ku. “Our government has supported this system 
on a bipartisan basis for decades, and this proven system of 
care will continue to make a difference in the future.”  n
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Making the Right  
Connections
GW’s New Institute for Neuroscience Explores the Mystery of Mental Illness 
His fingers articulated pinching, shifting, and stretching 
motions around his head to mime a dynamic series of cell 
migrations between the developing face and brain that occur 
roughly halfway through embryonic development in a mouse. 
“The brain is sending out a set of cellular ambassadors to 
instruct the periphery on how to develop so it’s ready for the 
brain and the brain is ready for it,” later explains LaMantia, 
an internationally renowned neuroscientist who came to GW’s 
School of Medicine and Health Sciences (SMHS) in 2010 from 
the University of North Carolina School of Medicine. “The 
idea that this is a target for disorders should be something 
everybody embraces. We have known for years that patients 
with a variety of behavioral disorders, including autism and 
schizophrenia, also have mild to severe facial anomalies that 
are thought to arise during development.” 
GWIN was established with the aim of revealing many 
such “targets” for mental illness through a focused, multidis-
ciplinary approach. LaMantia has assembled two dozen re-
searchers from across GW and partner institution Children’s 
National Medical Center with a wide range of neuroscience 
backgrounds to take on collaborative projects, including the 
basic science of brain development, its clinical relevance, and 
others. Specialist Norman Lee, Ph.D., professor of Pharma-
cology and Physiology, for example, draws from his research 
on gene networks and pathways relating to behavior, while 
Sally Moody, Ph.D., professor of Anatomy and Regenerative 
Biology, provides insights into genes involved in neural tube 
and craniofacial birth defects. 
Researcher Molly Huntsman, Ph.D., principal investigator 
at the Center for Neuroscience Research at Children’s Nation-
al, provides insight from her work on the development of in-
hibitory neurons in neural circuits. Vittorio Gallo, Ph.D., the 
Wolf-Pack Chair of Neuroscience and director of the Center 
for Neuroscience Research at Children’s National, contributes 
his experience exploring neural progenitor development and 
injury responses in the immature and adult brain. 
By synergizing all this expertise, GWIN seeks to under-
stand mental illness from a holistic perspective, including the 
molecular, cellular, and behavioral elements. “Putting to-
gether these labs will make a whole that is much bigger than 
the sum of its parts,” Gallo predicts. 
The institute’s multi-front approach reflects a growing phi-
losophy in neuroscience: By finding common ground, formerly 
disparate labs from various fields can collaborate and jointly 
delve deeper into heritable, genetic disorders that disrupt 
brain function, and, therefore, behavior. New ideas are in de-
mand, as the true cause of mental illnesses remains a mystery. 
Disorders like autism, fragile X syndrome, pediatric epilepsy, 
perinatal brain injury, and attention deficit hyperactivity dis-
order (ADHD) remain largely unsolved, but their symptoms 
demonstrate that complex behaviors, when disrupted, have a 
big impact on the quality of life. “That’s what we’re ultimate-
ly trying to shed light on,” LaMantia emphasizes. 
GWIN’s translational approach to neuroscience research 
puts a focus on the developing brain.  While the institute will 
not exclusively focus on children, its work will be caged in the 
Seated with his colleagues at a conference table, Anthony-Samuel 
LaMantia, Ph.D., founding director of the new George Washington 
Institute for Neuroscience (GWIN), intuitively used his hands when 
describing a stage in brain development.
By Peter Sergo     Illustration by Dan Winters 
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understanding that the onset of neurological 
diseases comes much earlier in life than scientists 
have previously believed.  One disorder of keen 
interest to GWIN is DiGeorge syndrome, a disease 
with wide-ranging signs and symptoms caused by 
a deletion of one copy of a small subset of the 
normal complement of genes on chromosome 22. 
Those who lack this network of genes often suffer 
physical malformations and various types of 
mental illness, showing that the missing genes are 
vital during early stages of development. Numer-
ous mental symptoms arise: 50 to 60 percent  
of children with DiGeorge syndrome suffer a 
psychotic break in late adolescence, 30 to 40 
percent are diagnosed with an autistic spectrum 
condition, 30 to 40 percent are diagnosed with 
ADHD, and roughly 10 percent are diagnosed as 
intellectually disabled. 
The localized nature of the deletion that causes 
DiGeorge syndrome provides an opportunity to 
zero in on genetic and molecular mechanisms 
that underlie normal and deviant development. 
“This genetic lesion gives us a node where a fairly 
small group of genes modulate cell proliferation, 
adhesion, and mitochondrial function,” LaMantia 
explains. “The missing genes set a dynamic range 
for other aberrant things to happen.” 
But despite the actual genetic deletion of 
DiGeorge syndrome being consistent, the conse-
quences are not. Tracing what happens isn’t simply 
a matter of identifying a wrongdoing mechanism. 
LaMantia suspects that a person’s unique genetic 
makeup, such as a missing set of genes — along 
with distinct environmental factors — plays into 
the behavioral outcomes of the disease. Further 
complicating matters is the possibility of a muta-
tion altering brain development at several points 
throughout its orchestration. “It’s a nightmare 
thinking about this in terms of therapeutic inter-
ventions. Where do you fix it?” he asks.
CORTICAL CONNECTIVITY
Discernible behavioral symptoms of psychiatric 
illnesses ultimately arise from disrupted electrical 
connections between nerve cells, much as palpable 
chest pains are elicited by a clogged coronary 
artery. The detective work needed to understand 
the cause of, say, schizophrenia demands a nuts-
and-bolts, neurobiological understanding of the 
disease. “It’s clear that there is a neurogenetic 
component,” observes Gallo, “but how does the 
genetic component become expressed, manifested, 
and translated into abnormal cellular structures?” 
Once a specific gene or set of genes is identified, 
Gallo says, the next step will be to understand how 
those irregular genes generate abnormal proteins, 
and how those proteins, in turn, generate aberrant 
nerve cell connections and functions.
Nerve cell interaction, or connectivity, is a key 
component in understanding how complex behav-
iors are disrupted in mental disorders, according 
to LaMantia. “My guess is that for all of these 
Team members, from left: Anthony-Samuel LaMantia, Ph.D.; Sarah Shomstein, Ph.D.; 
Anne Chiaramello, Ph.D.; Norman Lee, Ph.D.; and Judy Liu, M.D., Ph.D.
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diseases,” he says, “some aspect of the basic rules of 
connectivity is broken.”
In fact, LaMantia and many other neuroscientists 
now believe that most, if not all, behavioral and psy-
chiatric diseases — including autism, ADHD, bipolar 
disorder, and schizophrenia — are part of a broad class 
of diseases referred to as “disorders of cortical con-
nectivity.” All these disorders arise from the improper 
development of the cerebral cortex, particularly regions 
of the frontal cortex, which occupies the most anterior 
part of the brain. LaMantia describes this region as “the 
heavy lifter” because it’s the throne of executive func-
tions that include memory, selective attention, social 
interaction, language, learning, and cognition. 
Deciphering the link between the improper wiring 
of the frontal cortex (and the associated behavioral 
consequences) and a genetic source would be a huge step 
toward understanding psychiatric disease. A key goal 
of GWIN will be to define and assign specific functions 
to genes and sort out how they work together to control 
various aspects of cortical circuits’ wiring. “We have to 
understand how normal development occurs,” explains 
Gallo, “because it is the disruption of these pathways 
and their interactions that is modified in neurodevelop-
mental disorders.”
LaMantia likens the business of gaining a molecular 
understanding of neural development to that of cancer 
biology research 20 years ago, when it delved into signal-
ing pathways that regulate cell proliferation, apoptosis, 
and migration motility. “In the isolated instance of each 
of these detailed molecular experimental paradigms, 
you’re not necessarily identifying the target for therapy,” 
he says, “but rather looking at a piece and understanding 
how it goes slightly awry.” The subsequent step, he adds, 
would be to see what happens when they adjust this piece 
therapeutically and apply it to the brain.
ARRIVING LATE TO THE PARTY
Despite the neurodevelopmental hypothesis of mental 
illness that began to take hold in the late 1980s, this 
paradigm shift hasn’t translated into effective medi-
cine for many people with mental disorders. Overall, 
progress in reducing the morbidity and mortality of 
psychiatric diseases has been slow in comparison to that 
of cancer and cardiovascular disease. When speaking 
at GWIN’s inaugural seminar series in mid-September 
2010, Thomas Insel, M.D., the director of the National 
Institute of Mental Health and a friend of LaMantia’s, 
described existing treatment options as “not so good.” 
Insel conveyed that the challenges of diagnosing and 
treating mental illness are based on its lack of reliable 
biomarkers, the essential tools of objective diagnosis, 
making it one of the few areas of medicine that still 
relies on skills of observation. Since the cause of most 
mental disorders remains largely unknown, so, too, is 
a psychiatric patient’s response to treatment. And cure 
and vaccine are terms that still seem to have no place in 
the lexicon of treating mental disorders.
These disadvantages have snowballed to make mental 
illness the largest source of disability of all medical dis-
orders in the United States. Ninety percent of all suicides 
are due to mental illness, a total that surpasses the yearly 
death toll from homicides and AIDS, and the fiscal toll of 
mental illness is around $300 billion per year. 
When LaMantia considers the Herculean task that 
lies ahead of neuroscience, he thinks again of cancer. 
Oncology’s identification of targets for chemothera-
peutics is based on the understanding that the ways in 
which cells divide, move, and die are expressions of 
transformation and malignancy. 
Similarly, LaMantia sees the need to understand 
neuronal circuitry in terms of neurons themselves and 
how their processes grow. He wants to grasp how neu-
rons initially become specified to be what they are and 
— importantly — how they construct synapses to wire 
up with other neurons.
GWIN already employs strong scientists recognized 
for probing neuronal precursor specification and early 
patterning in morphogenesis, the stage when cells 
acquire the potential to blossom into a mature neuron. 
LaMantia intends to complement this effort by bolster-
ing research that focuses on the next step in neuronal 
development: synapse building. 
As a neuron differentiates, it puts out processes 
and makes connections with other neurons. LaMantia 
thinks this step is a crucial component in the origins of 
frontal cortex disorders. “We all believe that there are 
neurogenic proliferation and migration deficits in these 
disorders,” he says. “But where the rubber really meets 
the road is when they don’t wire up properly.” n
Nerve cell interaction, or  
connectivity, is a key  
component in understanding 
how complex behaviors are 
disrupted in mental disorders, 
according to LaMantia. 
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ou won’t find Lynn Goldman, M.D., 
M.P.H., stuck in a rut. The self- 
proclaimed adventurer has blazed  
an indomitable and vibrant career 
path, serving in such positions as 
pediatrician, epidemiologist, professor, investigator, and 
government appointee. Countless people and places have 
reaped the benefits of her broad work in environmental 
health practice and chemical regulatory policy — efforts 
that were recently recognized with a prestigious award 
from the Heinz Family Foundation.  
Goldman has a simple explanation for a career that 
is as varied as it is venerated: “I like new challenges,” she 
says. “I haven’t done the same type of thing my whole life 
because I like to make an impact in a lot of ways.”
 In August 2010, Goldman took on her newest chal-
lenge when she was appointed as the third dean of GW’s 
School of Public Health and Health Services (SPHHS). 
The school — which boasts seven departments, has one 
of the fastest-growing research portfolios of any school  
of public health in the nation, and is developing plans for 
a new state-of-the-art building — has an exhilarating tra-
jectory of change that keeps pace with Goldman’s own.
“One of the exciting things about SPHHS is that it’s 
still growing and developing,” she says. “I am excited 
to build upon the good work that has been done so far, 
most recently under the leadership of my colleague, Jo-
sef Reum, who served with such distinction and passion 
as interim dean for the last two years. It’s part of what 
convinced me to come here.” Reum, Ph.D., is a profes-
sor of Health Policy and of Health Services Manage-
ment and Leadership at the school and now serves as 
senior associate dean.
In Goldman, GW has found exactly what it needed: 
a dynamic individual who could bring multifaceted 
experience to the post. “With her breadth of experience 
in the fields of children’s environmental health, public 
health practice, and chemical regulatory policy, as well as 
her distinguished career in government, Lynn Goldman 
is ideally suited to lead our rapidly emerging School of 
Public Health and Health Services,” said GW President 
Steven Knapp, in announcing Goldman’s appointment.
Goldman launched her public health career in 1981, 
when the general belief was that low-level exposure to 
environmental contaminants wasn’t harmful. Residents 
of now-infamous Love Canal in Niagara Falls, N.Y., 
for example, were told by government officials that 
the nearby hazardous waste site would not induce any 
adverse health effects. But during a research fellowship 
at Children’s Hospital and Research Center in Oakland, 
Calif. — where she investigated the health impacts of 
toxic chemical exposure on children living near Love 
Canal — Goldman contributed to early findings linking 
birth and growth problems to the site itself.
The results, which later became the subject of inter-
national attention and controversy, shifted both general 
beliefs about public health and the scope of Goldman’s 
career. She decided to dedicate herself to fighting for the 
underdog. “When public health issues affect small groups 
of people, rather than the general public, those groups 
can be marginalized,” she explains. “In the U.S., our big-
gest challenges are the inequities in health status.”
Goldman followed that experience with a posi-
tion as an epidemiologist at California’s state health 
department, where she found she had a strong interest 
in children’s health. There, she established a blood-lead 
surveillance system, laying the groundwork for Califor-
nia’s childhood lead poisoning prevention program.
In 1993, President Bill Clinton appointed Goldman 
to serve as assistant administrator for the Environ-
mental Protection Agency’s (EPA’s) Office of Chemi-
cal Safety and Pollution Prevention, where she guided 
the agency’s expansion of “right to know” laws under 
the Toxics Release Inventory program and overhauled 
the nation’s pesticide laws. Later, she helped advance 
the Food Quality Protection Act of 1996, the first law 
explicitly requiring measures to protect children from 
lead poisoning and pesticides.
Goldman joined the faculty at the Johns Hopkins 
Bloomberg School of Public Health in 1999 with the 
Setting the Pace  
          for Public Health
LYNN GOLDMAN APPOINTED NEW DEAN OF  THE  SCHOOL OF  PUBLIC  HEALTH AND HEALTH SERVICES
Y
By Adrian Granzella Larssen     Photography by Holger Thoss 
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primary intention of pursuing her own research. While leading 
investigations on children’s health and emergency response, 
however, she discovered a passion for academics. So when it 
came time for the next step in her career, Goldman found that 
GW — a university with a strong reputation for policy work — 
was an ideal fit. “Here at GW, and in the nation’s capital, you 
can play a very powerful role in policymaking,” she says. 
In her new post as dean, Goldman will use her passion 
for public health, education, and policy-shaping to guide her 
decisions. She hopes to build upon SPHHS’ rising research 
portfolio in areas such as HIV/AIDS, environmental health, 
and health policy.  Fostering strong relationships and collabo-
rations between departments and with federal and interna-
tional organizations is another goal.  
In addition, Goldman will oversee another significant 
change at SPHHS: the development of a new building (see be-
low). The sustainably designed research and educational facil-
ity will, for the first time, provide a central home for SPHHS, 
facilitating greater collaboration among faculty, students, and 
staff. “The new building is a vital part of the school’s future,” 
she emphasizes. “The physical space will give us an identity 
and make it possible for us to become an even greater, more 
influential institution in the decades to come.”
Key to that identity, says Goldman, is blazing a continu-
ous path of learning and imbuing wisdom in future gen-
erations. “We need to teach the skills that will enable our 
students to acquire more knowledge over time,” she says. 
“Learning is a lifetime experience.” n
Healthy Home Design
SCHOOL OF PUBLIC HEALTH AND HEALTH SERVICES 
MAKES PLANS FOR NEW BUILDING
At the conclusion of its May 2010 meeting, The George 
Washington University’s Board of Trustees unanimously 
endorsed one of the Medical Center’s most important stra-
tegic priorities: construction of a new building to house the 
School of Public Health and Health Services (SPHHS). The 
new building will, for the first time in the 13-year history of 
SPHHS, serve as a consolidated home for most of the school’s 
faculty, students, and staff. 
The technically advanced facility, scheduled to be  
completed in the summer of 2014, will provide a central 
location for research in public health, facilitating and 
enhancing synergies among SPHHS’ seven diverse depart-
ments. The building will also serve as 
an essential convening place for 
collaboration among SPHHS, govern-
ment agencies, and international public 
health organizations.
The new structure will be built on 
land that is currently occupied by GW’s 
Warwick Building at the intersection  
of 24th and K streets on Washington  
Circle. The building will feature 
115,000 square feet of state-of-the-art 
classroom facilities, research labs, de-
partmental and office space, and confer-
ence rooms, at a cost of $75 million.
Current plans call for the building to 
be constructed with a range of “green” 
materials and sustainable features. The 
facility is targeting a Silver rating under 
the Leadership in Energy and Environ-
mental Design (LEED) Green Building 
Rating System of the U.S. Green Building 
Council.
Lynn Goldman, M.D., M.P.H, the 
new dean of SPHHS, said the first-ever 
home for the seven departments, students, faculty, and staff 
is a vital part of the school’s future. “This new building will 
enable GW’s School of Public Health and Health Services 
to move to the next level of excellence in our education 
and research programs. It’s hard to think of anything more 
important to the school’s long-term future and its ability 
to grow and attract the best faculty and students in public 
health. I’m very excited to be a part of the project,” she said. 
The University expects to begin removing the Warwick 
Building and start construction on the new SPHHS building 
in the spring of 2012. n	 	 								
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ub-Saharan Africa bears 24 percent  
of the world’s disease burden, but has 
just three percent of its health work-
force. Training — and retaining — 
physicians on the continent has been an ongoing 
challenge. Impoverished health systems, the 
world’s highest prevalence of HIV/AIDS, and the 
constant lure of emigration take heavy tolls on  
the graduates of the 160 medical schools in sub- 
Saharan Africa.
Recently, the National Institutes of Health 
(NIH) tapped the School of Public Health and 
Health Services to serve as the coordinating center 
of its Medical Education Partnership Initiative 
(MEPI), a $12.5-million, five-year project to in-
crease medical education capacity at 12 participating 
medical schools in sub-Saharan Africa. Researchers 
Fitzhugh Mullan, M.D., Murdock Head Professor 
of Medicine and Health Policy, and Seble Frehy-
wot, M.D., M.H.S.A., assistant professor of Health 
Policy and of Global Health, will serve as principal 
investigators on the project. They will assist medical 
schools from 12 countries in enhancing the quantity, 
quality, and retention of their graduates. 
MEPI emerged from the 2008 reauthorization 
of the U.S. President’s Emergency Plan for AIDS 
Relief (PEPFAR), which included a mandate to 
train 140,000 new health workers in Africa over 
five years. Through the initiative, the NIH seeks 
to expand medical education and build health care 
capacity to combat HIV/AIDS, while also creating 
a workforce that can address other local health 
problems across the spectrum of diseases. 
“It is vital that we develop medical and 
research capacity in sub-Saharan Africa so that 
advances can be quickly adapted for local use,” 
said NIH Director Francis Collins, M.D., Ph.D., 
when announcing MEPI. “This program will not 
only strengthen medical education to produce 
much-needed caregivers, but will also generate 
well-trained researchers.”
GW will work with the participating medi-
cal schools to establish baseline assets and needs. 
“We want to get a sense of how their educational 
engines function in terms of the training they 
offer, numbers of people trained, and where their 
graduates practice,” explains Mullan. 
Following the initial assessments, GW and its 
local partner, the African Center for Global Health 
and Social Transformation, led by Francis Omas-
wa, M.D., will develop technical support plans 
that address the specific needs of each school. GW 
will link the schools to resources and expertise to 
enhance their basic and clinical science teaching. 
Communication is an essential aspect of the 
project. GW will establish an electronic platform 
to support information sharing, mutual curricular 
projects, and data collection between the par-
ticipants. In addition to regular site visits to each 
school, the GW team will coordinate an annual 
symposium for the participants. 
Despite the challenges presented by the scale 
of the project, Mullan and Frehywot recognize the 
enormous potential MEPI offers for both analysis 
and contribution. “Assisting these institutions is 
a rare opportunity to conduct educational service 
and, if we succeed, impact the medical education 
systems of an entire continent,” Mullan says. n
Moving Medical Education in 
Sub-Saharan Africa  
Toward a Sustainable Future
S
By Thomas Kohout
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hen Tim Russert, the longtime moderator of 
Meet the Press, died in the offices of WRC-TV 
in Washington, D.C., he did not succumb to 
a “massive heart attack,” as some reports 
suggested. Instead, he died of a sudden arrhythmia — some-
times called “sudden cardiac death” — when his heart’s 
electrical pulse lost sync and went haywire. 
An autopsy found that a piece of plaque had broken free in 
one of Russert’s arteries, lodging in a blood vessel that feeds 
the heart. That section of Russert’s heart lost oxygen. This 
ischemia, in turn, induced ventricular fibrillation — uncon-
trolled twitching of the muscle fibers in the lower chambers of 
the heart. Instead of pumping blood, Russert’s heart went into 
useless spasms. The 58-year-old died within minutes. 
“Instead of following the main pacemaker of the heart, the 
cells that receive only partial oxygen start screaming ‘there’s 
something wrong here,’” says cardiac physiologist Narine 
Sarvazyan, Ph.D. “This message, whatever it is, interferes with 
the heart’s normal electrical pattern. The heart goes into fibril-
lation, and the outcome is usually deadly.” 
According to the American Heart Association (AHA), 
some 300,000 Americans receive emergency treatment each 
year owing to sudden cardiac arrest. Yet scientists don’t fully 
understand how ischemia causes fibrillation — the cellular 
message that “something’s wrong” with the heart. 
“We would like to understand why when someone has a 
heart attack, some people — like Tim Russert — immedi-
ately have lethal arrhythmia, and some people don’t,” says 
Matthew Kay, D.Sc., P.E., an assistant professor in GW’s 
School of Engineering and Applied Science who works 
closely with Sarvazyan. “That’s the big question.”
That question has prompted Sarvazyan, an associate pro-
fessor in GW’s Department of Pharmacology and Physiology, 
and her interdisciplinary team to launch a series of projects 
to understand heart arrhythmias at a deep level. 
Their projects span the range of molecular, cellular, 
tissue-based, whole-organ, and animal studies. In 
addition, Sarvazyan’s team has begun research that 
could one day lead to a “Band-Aid” for the heart — 
patches of stem cell-derived cardiac tissue engrafted 
onto damaged areas. 
The scary thing about sudden cardiac attacks is that they can just come out of nowhere,” says Luke Swift, a Ph.D. student 
co-mentored by Sarvazyan and Kay. Swift attaches 
a still-beating rat heart to a tiny spigot and dips 
the heart into a small, clear plastic box attached 
to a lab stand. Air is bubbling into the liquid-filled 
Restoring the Rhythm
 A t t a c k i n g  A r r h y t h m i a  w i t h  G e n e t i c s
W
By Brian Vastag     Illustration by Stuart Bradford 
A rat heart injected with voltage-sensitive dye is 
bathed in green light to show electrically active cells.
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box, and tangled wires snake from the apparatus 
to equipment that takes images of the heart with 
two cameras: one recording electrical activity, a 
second capturing metabolic action. 
This imaging system, being developed by 
Kay, will provide crucial data about where and 
when low-oxygen conditions in the heart trig-
ger arrhythmias. In particular, the cameras will 
pinpoint “hot spots” where irregular rhythms 
originate. In patients with certain types of arrhyth-
mias, cardiologists can zap, or “ablate,” these hot 
spots with a spark of electricity to the area. At The 
George Washington University Hospital, special-
ists regularly perform such procedures, says Marco 
Mercader, M.D., a clinical electrophysiologist who 
collaborates with Sarvazyan and Kay. Mercader 
says the ablation procedure successfully resolves  
arrhythmias in about 70 percent of patients, but 
with the benefit of better imaging, those figures 
could be better still. 
With the rat heart prepared, Ph.D. student Huda 
Asfour consults three computer screens in a corner 
of the cramped experiment room. An electrical 
engineer, Asfour writes computer code that pro-
cesses the heart images for closer scrutiny. As Swift 
dips two metal leads into the bubbling heart box, 
the monitors blink to life, displaying a trace of the 
heart’s electrical activity. The rhythm is erratic at 
first, then settles into the familiar spike-and-line 
pattern of a normal heartbeat. 
Asfour positions a camera about a foot in front 
of the heart, then bathes the heart in green light. 
She explains that the light excites a voltage-sensitive 
dye — Swift injected it into the heart earlier — that 
fluoresces as cells become electrically active. The 
dye allows the camera to record the precise patterns 
of electrical activity swirling through the heart. 
Swift tightens a small suture around the coro-
nary artery at the top of the heart, choking off  
oxygen. The team wants to see how this local-
ized ischemia impacts the heart’s normal electrical 
rhythm. A second camera records the fluorescent 
intensity of a naturally occurring compound called 
NADH. The compound glows with increasing 
intensity as the tissue is starved of oxygen. Swift 
switches off the overhead light and the room glows 
green. “Now this looks like science,” Swift says, 
smiling. 
The room gets crowded and activity picks up  
as Kay and a Ph.D. student enter. The ECG rhythm 
has changed; it is double spiking. The heart is 
contracting twice rapidly, a condition that may 
complicate data analysis. Kay and Swift fiddle with 
the tubes and wires poking into the heart box. 
Kay suggests warming the heart. The ECG rhythm 
settles momentarily, then reverts. “It’s double spik-
ing again,” Asfour says. 
When the rhythm stabilizes, Asfour runs the 
cameras. She starts them with a click, and data 
from the devices flows into the computer. In just 
a few seconds, the data run is over. Minutes later, 
Asfour runs the cameras a second time. She’s unsure 
if the data will be clean enough to work with — the 
double spikes have returned. 
“The studies are technically challenging,” Kay 
says, adding that the team did retrieve useful data 
from the experiment, even though things didn’t 
go according to plan. “Usually about half the time 
we’re successful at collecting the data we need to 
answer our questions.” 
And so, in fits and starts, science moves ahead.
Days later, Kay discusses the heart imaging ex-
periments, studies for which he and Sarvazyan have 
received a new five-year grant from the National 
Institutes of Health. While inducing ischemia in the 
rat heart, the metabolic imaging camera pinpoints 
small areas screaming for oxygen. That data is then 
overlaid on images of electrical flow around the 
heart. Together, the two data sets reveal where and 
when the ischemic regions trigger arrhythmia. So 
far, the studies have shown that premature beats — 
a type of arrhythmia — often begin at the boundary 
of the ischemic regions. 
It’s a Tuesday afternoon, and Sarvazyan has gathered her team for a meeting. Assistant Research Professor Zaruhi Karabekian, Ph.D., 
presents the latest experiments in Sarvazyan’s 
second project, the effort to design Band-Aids for 
the heart. Worldwide, in a series of human trials, 
researchers are attempting to repair heart damage 
using stem cells derived from the patients’ own 
Some 300,000 Americans each year receive 
emergency treatment owing to sudden  
cardiac arrest. Yet scientists don’t fully 
understand how ischemia causes fibrilla-
tion — the cellular message that “some-
thing’s wrong” with the heart.
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blood and bone marrow. But these studies have shown only 
transient benefits, and Sarvazyan says one reason is that the 
injected cells fail to engraft in the damaged heart.
Ultimately, Sarvazyan believes patches of heart cells grown 
from either embryonic stem cells or adult cells returned to the 
embryonic state could be designed to permanently stitch them-
selves into the heart. In a step toward that goal, the team has 
engineered a new type of stem cells to produce surplus sticky 
proteins on their surface. These two sticky proteins, called N-
cadherin and connexin-43, help bind patches of the new heart 
cells to the existing tissue. Whereas N-cadherin aids the cells’ 
connections, connexin-43 helps them fire together, a discovery 
the team made three years ago. 
Next, a student who spent her summer in the lab before 
heading to medical school at GW, Sana Idrees, presents the re-
sults of her experiments. She’s been working with Karabekian 
on another aspect of the heart Band-Aid project: reducing the 
immune system profile of newly grown heart cells, a project 
for which Karabekian recently received an AHA grant. Every 
cell in the body carries a passport, Sarvazyan explains, called 
the major histocompatibility complex (MHC). If a cell has the 
wrong passport — meaning the cell has been transplanted — 
the immune system will attack it as a foreigner. In ongoing 
clinical trials of various types of stem cells for heart repair, 
researchers are finding that after several weeks, all evidence of 
the implanted cells has disappeared. The implanted cells don’t 
engraft in the heart, where they could provide a long-term 
boost of pumping power. To make viable heart grafts that 
don’t suffer this fate, the team hopes to squelch production of 
MHC. Cells without an MHC passport will, in essence, be 
invisible to the immune system. Such a step could 
be key to developing a viable heart therapy, says 
Sarvazyan. “We really need to … understand how 
to implant these heart stem cells in a way that is 
durable, so the cells stick,” she adds. 
The field of cardiac stem cell therapy is nascent, 
according to Sarvazyan, similar to where bone mar-
row transplantation for leukemia was decades ago. 
“We really need to go back to the blackboard and 
understand the basics of cellular activity” before 
cell transplants can be improved to help heart pa-
tients, she says. If a pending NIH grant is funded, it 
would provide Sarvazyan the means to scale up the 
heart-patch experiments in live animals, to see if her 
team can make tissue patches that engraft properly 
in the heart and conduct electrical signals. 
Of course, there are no guarantees that those 
experiments, if funded, would work. And so Sarva-
zyan takes the long view, as any basic scientist must. 
She knows that the human health applications of 
her work are years, if not decades, off. The cardiac 
physiologist is moved by the same desire that drives 
every other scientist: the quest to understand, to 
accumulate knowledge, to explain some corner of 
the universe. 
Not that it’s easy. “I tell my students when they 
come into the lab that out of 10 experiments, maybe 
only one will work,” she says. “You have to have 
enough drive and feel enough inspiration from those 
successes to push you through to the next set.” n
Matthew Kay, D.Sc., P.E., and 
Narine Sarvazyan, Ph.D., have 
formed an interdisciplinary col-
laboration to find a solution to 
lethal arrhythmia.
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n the fifth floor of Children’s National 
Medical Center, in the southeast corner 
of a large lab, is a cubby with a desk, a 
computer, two bike helmets, and three 
phones. From this understated work-
space, Eric Hoffman, Ph.D., directs one of the world’s largest 
centers for the study of genetic disorders — the Center for 
Genetic Medicine Research. 
Hoffman, a family man who spends most of his free time 
outdoors, dislikes doors or walls in his workspace. He thinks 
academic medicine is too “siloed,” and believes that more 
openness means more collaboration. He explains his science 
by using metaphors of Slinkys, Tinker Toys, and cookbook 
recipes. He laughs a lot. It’s not yet 11 a.m., and Hoffman 
has already advised on a grant application, spoken with mem-
bers of his lab, and interviewed a prospective nurse. Now, 
he is explaining a new treatment possibility for Duchenne 
muscular dystrophy, the disease that best defines his research 
and that lies closest to his heart. 
Children’s National serves as the home of two GW School 
of Medicine and Health Sciences (SMHS) departments:  
Pediatrics and Integrative Systems Biology, which Hoffman 
chairs. Hoffman, who is also a professor of Pediatrics at 
SMHS, landed at Children’s National 10 years ago, after a 
long stint at University of Pittsburgh School of Medicine and 
several years of teaching and postdoctoral work at Children’s 
Hospital Boston and Harvard Medical School. He has been 
awarded fellowships from the Howard Hughes Medical Insti-
tute, the Muscular Dystrophy Association, and the American 
Heart Association. Now, he runs a lab that covers thousands 
of square feet and spans two floors, staffed by 35 faculty 
members and 200 researchers.
Duchenne is a muscle-wasting disease that strikes one in 
every 3,500 children, mostly boys. It is an X-linked recessive 
trait — carried on the X-chromosome and more commonly 
expressed in males — but, like dwarfism, occurs spontane-
ously more often than it is passed down. Typically, children 
with the disease develop normally for their first few years, 
and then begin to have trouble climbing stairs, getting up 
from the ground, or breaking into a run. Most are in wheel-
chairs by their teens, and as the disease progresses, eventually 
require respirators to breathe. The majority die in their 20s 
or 30s from heart failure. There is no cure. 
Hoffman is one of the leading researchers working on a 
new treatment option for Duchenne called exon skipping. 
He has high hopes for the therapy, but worries that existing 
regulatory rules and overwhelming cost will slow efforts to 
get the drug approved and made widely available to patients. 
“The real tragedy is if something works that can help 
these patients, and we can’t deliver it,” he says. 
H
offman’s interest in muscular dystrophy can be traced 
back to his postdoctoral days at Harvard, when 
he first began manipulating the genes of fruit flies, 
changing their eye color and turning their wings backward. 
He spent long hours in the lab and often took the flies home 
with him. One Thanksgiving, he stationed a jar of fruit flies 
beside his plate during the meal to be sure the flies weren’t 
having “inappropriate sex,” which might compromise his 
research. “Of course,” he recalls, “there’s only so long that 
you can turn their eyes [different] colors and their wings 
backward before you start to ask the question: How is this 
helping humanity?” 
So he shifted his focus. Using what he’d learned  
Working in Genes
Pediatric Researcher Eric Hoffman Leads the Attack  
on Duchenne Muscular Dystrophy
By Jenny Marder     Photography by Holger Thoss 
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manipulating genes, he turned his attention to human 
genomes. Soon after, his Harvard research team, led by 
Louis Kunkel, Ph.D., became the first to identify and 
clone the gene responsible for muscular dystrophy: the 
DMD gene. 
It was 1986, and little was known about the disease 
at the molecular level. But suddenly, characteristics of 
muscular dystrophy that had baffled researchers began to 
make sense. Most genes have about 30,000 DNA units. 
The DMD gene, they found, had more than two million, 
making it the largest known human gene. Its sheer size 
made it more prone to spontaneous mutations, which ex-
plained why the disease was so common. And, research-
ers discovered, it coded for a protein critical to muscle 
function. They named the protein dystrophin.
The job of dystrophin is to reinforce the walls of 
muscle cells, which are long and tubelike, and which 
constantly stretch apart and slam together as people 
move. The dystrophin protein gets plastered along the 
muscle walls, providing the strength and support needed 
during muscle contraction. But mutations can cause the 
gene translation process to go haywire. 
Genes are divided into exons and introns. Exons 
code for protein; introns, also known as “junk” DNA, 
are the stuff in between, and unnecessary for protein 
production. During gene translation, the 79 exons that 
make up a normal dystrophin gene are spliced from 
the gene’s introns and pieced together like a puzzle into 
messenger RNA (mRNA), which then translates into the 
dystrophin protein. When the exons are appropriately 
assembled, they form a reading frame in which each 
three-letter section of mRNA translates into one amino 
acid. 
The structure of this frame is enormously impor-
tant. If any part of any of these 79 exons is damaged 
or deleted through a mutation, then the message can 
get scrambled. This can prevent the mRNA from being 
assembled in a readable form, resulting in a nonfunc-
tional dystrophin protein. Hence, Duchenne. “If you’re 
missing it, you start blowing holes in your plasma 
membrane,” Hoffman says. “And that’s the first key 
finding to diagnose a patient with Duchenne. You might 
actually see enormous amounts of muscle guts in their 
blood.”
Exon skipping drugs, a form of antisense compound 
that interact with nucleic acids to modify gene expression, 
are sometimes described as “molecular patches.” They 
seal and repair the damaged fragments of the mRNA. 
“What the exon skipping drugs do, in lay terms, is go 
into the genetic molecule, trim the ends around that 
deleted area, and splice them back together. And then the 
message makes sense again,” says Valerie Cwik, M.D., re-
search and medical director for the Muscular Dystrophy 
Association. Exon skipping would not cure Duchenne, 
but researchers believe it could substantially reduce symp-
toms, by remodeling a Duchenne patient’s mRNA. 
I
n 2000, two Washington lobbyists, Joel and Dana 
Wood, had a disturbing meeting with their son’s pre-
school teacher. “She was being overly emotional about 
our need to get him checked out,” Joel Wood recalls. 
“She’d taught hundreds of students and had never seen a 
child at the age of three who struggled to get up the stairs 
as much as James did.” They took him to Hoffman’s lab 
for a dystrophin identifier test. Within a week, they had 
the full diagnosis: Duchenne muscular dystrophy. James 
was missing exons 44 through 52. 
“It’s a devastating diagnosis when it’s your child,” 
Joel Wood says. “And I think anyone faced with that 
pretty much takes an inventory of their resources and 
figures out what they can do.” Research for the disease 
was grossly underfunded, the couple discovered, and 
what little funding did exist was divided among three 
government agencies. 
Only months earlier, Hoffman had transferred from 
the University of Pittsburgh to Children’s National in 
Washington, D.C., where he felt he would be better po-
sitioned to advocate for federal support. His initial goal, 
Normal muscle has dystrophin protein around each muscle cell (red circles, left panel).  Muscle from DMD boys (and 
dogs) is missing dystrophin (center panel). Intravenous delivery of exon skipping drugs restore dystrophin (right panel).
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cloning the first Duchenne gene, had been real-
ized, but he continued to feel a strong obligation 
to deliver something to patients and their families. 
“I am quite focused on bringing therapeutics to 
these patients,” he says. “These kids and their 
families are my bosses.”
As it turned out, Duchenne was getting only 
five percent of the amount of federal funding that 
cystic fibrosis received, Hoffman recalls: “It was 
dismal, and nothing was being translated to the 
patients.” Hoffman and the Woods mobilized 
their efforts. They worked with members of 
Congress to pass the MD CARE-Act (Muscular 
Dystrophy Community Assistance, Research, 
and Education Act), which mandated that the 
government devote more attention and capital to 
muscular dystrophy. They led a lobbying effort 
to secure $60 million from the Department of 
Defense. The Woods launched the Foundation to 
Eradicate Duchenne, which has raised more than 
$10 million. 
“The scientific world was alien to me before 
my son’s diagnosis, and I think the political world 
was just as mystifying to Eric,” Joel Wood says. 
“But he has very sophisticated political skills. He 
has an amazing ability to speak in plain English 
and make things understandable.”
  
I
n the lab and in the clinic, studies are advanc-
ing, thanks in part to what Hoffman and the 
Woods accomplished on Capitol Hill. After 
studies on Duchenne mouse models and human 
cells indicated that exon skipping drugs could 
activate dystrophin production, Hoffman’s lab 
scaled up its research to study dogs with the 
disease. Duchenne in dogs is swift and fierce. The 
dogs usually get sick and die within six months. 
The dogs in the study had a point mutation in 
exon 7 of their dystrophin gene. After roughly six 
months of treatment with exon skipping drugs, 
the dogs began producing dystrophin again, at 
about 20 percent of normal levels in all skeletal 
muscles. And by every criterion studied — walk-
ing, running, eating, and drooling — the dogs’ 
muscle movement improved.
Results have also been promising in humans. 
Early-phase trials showed that the drugs appear to 
trigger dystrophin production in human skeletal 
muscles with no serious side effects. In another 
still-unpublished but public trial, 19 boys were 
treated for 12 weeks with varying doses of exon 
skipping drugs. Responses were varied, but in 
one case, nearly 50 percent of muscle fibers tested 
positive for some dystrophin after treatment. “It’s 
the first time anybody’s been able to get apprecia-
ble amounts of dystrophin back into the muscle,” 
Hoffman says. 
Some are more cautious. While most skeletal 
muscles responded well to the drug, delivery to 
the heart has been less effective, Cwik says. But 
Hoffman hopes to see future research confirm 
that higher doses can fix that problem.
     
E
xon skipping research is pushing regulato-
ry agencies to consider questions that may 
soon apply to other areas of personalized 
medicine as well. Each drug, for example, needs 
to be tailored to the exact spot on the gene where 
the mutation occurs. “You need different drugs 
for different patients with an already rare disor-
der,” Hoffman says. To avoid sending each drug 
variation through a lengthy approval process, 
researchers are working instead to get the drug 
approved as a class. 
The cost is also daunting. Developing the drug 
to treat three dogs cost nearly $1 million. 
But after 25 years of research, Hoffman says, 
DMD experts are finally building a good “race-
horse. . . . It’s certainly the best place it’s ever 
been,” he says. “There’s a lot more rationale and 
knowledge going into this, and a much more coor-
dinated international effort.”
In the meantime, Wood is hoping to get his 
son, now 13 and recovering from a broken femur, 
treated with exon skipping drugs as soon as pos-
sible. “I have great confidence that this has no sig-
nificant side effects,” he says. “The alternative is a 
disease that’s got a 100 percent mortality rate.” 
For now, the Wood family has to wait out the 
research and the regulatory process. “It’s a very 
tough thing, especially when your kid is suffer-
ing,” Wood says. “I know we’re going to get there. 
What I don’t know is whether it will come in time 
for my son.” n
“ I am quite focused on bringing therapeutics  
to these patients. These kids and their  
families are my bosses.”
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he southeast African country of Mozam-
bique has endured a tumultuous past. 
Battered by civil war until 1992, the na-
tion now faces an enemy just as fierce: HIV/AIDS. 
Though modest in size — about half the size 
of Alaska — the country has the fourth-largest 
number of people living with HIV in the world. 
Approximately 1.8 million citizens, or nearly 16 
percent of the country, are infected, and thou-
sands are born with the virus each year. 
Far away, in a quiet laboratory in GW Medi-
cal Center’s Ross Hall, Jeanne Jordan, Ph.D., 
professor of Epidemiology in the School of Public 
Health and Health Services, seems removed from 
this crisis. But since witnessing the epidemic last 
year during a visit to Mozambique, the researcher 
has been determined to have an impact. 
Jordan’s inspiration stems from a meeting with 
Ilesh Jani, M.D., Ph.D., director of Mozambique’s 
National Institute of Health. In recent years, the 
institute has focused on the country’s youngest 
HIV/AIDS patients by launching an Early Infant 
Diagnosis plan in 2007 to identify HIV-positive 
babies and treat them as soon as possible. Under 
the plan, rural health center staffers are trained 
to collect dried blood spots for HIV diagnosis. 
With large-scale infant diagnosis under way, the 
challenge now facing the institute is timing. Under 
the current diagnostic method, dried blood spots 
are shipped from village health clinics to provin-
cial labs, and then to one of two central reference 
laboratories in the country for testing. By the 
time the results get back to the local clinics, two 
months or more may have elapsed. For the fami-
lies, who may hear the results even later due to 
Mozambique’s poor communications infrastruc-
ture, that wait is too long. 
Jordan and Jani’s meeting, however, sparked 
an exciting idea. “We thought it would be re-
ally effective to decentralize the process so that 
provincial labs could do the testing rather than 
having to send it off to some place that might 
be hundreds of miles away,” Jordan recalls. By 
performing tests closer to the point of care, work-
ers could shorten the time between identifying 
HIV-positive infants and getting those infants 
into treatment. This, they thought, was something 
that could dramatically improve outcomes and 
save young lives. 
But there was a reason no one had tried it 
before: Provincial labs in Mozambique are rarely 
more sophisticated than a single room with a sink, 
refrigerator, and microscope. Provincial testing 
“couldn’t be done with the current process used 
in the central reference lab because of the cost of 
the equipment, the highly complex technology, 
and the training needed,” Jordan explains. But 
she saw a potential way to circumvent that chal-
lenge, and, since her return to the United States, 
has been evaluating virtually instrument-free HIV 
detection tests for use in even the most basic labs.
Diagnosing newborns with HIV poses a 
unique challenge. Unlike adults, who are tested 
for the presence of HIV antibodies, infants must 
be tested for HIV genetic material itself. Because 
maternal IgG antibodies cross the placental 
Tools for the Field
INVESTIGATOR JEANNE JORDAN SEEKS A 
SIMPLE AND EFFECTIVE TOOL FOR INFANT  
HIV TESTING IN RURAL LABS
T
By Adrian Granzella Larssen 
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barrier, children cannot be tested for 
their own antibodies to HIV without 
risk of a false-positive test until they 
are about 18 months of age. “But by 
18 months, infected infants would be 
well on the way to being extremely ill 
or dying,” says Jordan, adding that 50 
percent of babies born with HIV and 
left untreated die before their second 
birthday. “It’s really essential for these 
infants to have access to a molecular 
test early in their lives to determine if 
they need to be in treatment.”
The internationally accepted diag-
nostic approach for infant HIV testing 
is twofold. First, technicians extract 
nucleic acid from a dried blood spot. 
Next, they conduct amplification tests 
of the extracted material for HIV-1. 
Highly trained technicians, specialized 
equipment, and extensive protocols are 
required for both steps, so an instru-
ment-free methodology must address 
them in tandem. 
Jordan identified HandyLab, a 
Michigan-based company that was de-
veloping reagents that could be put on 
an automated extraction instrument. 
Interested in translating HandyLab’s 
techniques into a manual approach, 
Jordan worked with the company to 
develop an extraction method that 
would require only the use of a mag-
net, heating block, and pipettes. 
BioHelix Corporation, a Massachu-
setts-based startup, was a prime candi-
date for the second step in the process. 
The company had been working on a 
nucleic acid amplification test using a 
disposable cassette-based method. Its 
approach, too, required only simple 
devices. “You could essentially even 
use a car battery or solar panel as your 
power source for the heating block that 
is needed for the isothermal amplifica-
tion step,” Jordan notes. 
Though these approaches differ 
from the standard protocols, Jordan 
hopes that they will be just as effective 
in detecting HIV in infants. So far, re-
sults are promising: The methods have 
“very good correlation and a very good 
level of sensitivity,” she says. Because 
most samples she has accessed are 
subtype B cases from the United States, 
Jordan is partnering with two labs spe-
cializing in international work to better 
diagnose different HIV subtypes, 
including subtype C, which is the most 
common type in Mozambique. 
The next step will be translating 
this lab work into the field. Jordan has 
partnered with the Elizabeth Glaser 
Pediatric AIDS Foundation (EGPAF), 
the Association of Public Health Labo-
ratories (APHL), and Jani to submit a 
proposal to Grand Challenges Canada 
(a not-for-profit organization dedicated 
to improving health in developing 
countries). The proposal, if accepted, 
will provide comprehensive training, 
protocols, and quality measures for 
provincial lab technologists in two 
laboratories in Mozambique. Mean-
while, EGPAF, which supports the 
national HIV program in four local 
provinces, will enroll infants in nearby 
clinics for implementation research. 
The project will evaluate — in a true-
to-life setting — how the instrument-
free approaches compare to the current 
detection methods. 
“We’re excited to bring Dr. Jordan’s 
work to the field, where it has the real 
potential to save many lives,” says 
Nicholas Hellmann, M.D., EGPAF’s 
executive vice president of medical  
and scientific affairs. “For us, time is  
of the essence for identifying and treat-
ing HIV-positive infants. Working in 
local settings with relatively low-tech 
solutions is often the key to scaling 
up treatment for the most vulnerable 
populations.”
Jordan is eager to see how these 
methods can improve the health land-
scape in Mozambique. In the mean-
time, she’s looking even farther ahead. 
She’s identified two companies — Mi-
cronics, in Redmond, Wash., and Wave 
80 Biosciences, in San Francisco — 
that are developing true point-of-care 
diagnostic tools. The goal is to produce 
a small instrument activated by a lim-
ited power source that would combine 
the extraction and amplification steps 
into one, giving results directly from 
blood or dried blood spots. It may be a 
year or more before testing can begin, 
but the possibilities are promising. 
“We hope to move the testing from 
the provincial labs to local clinics and 
maternity hospitals,” says Jordan, 
“where nurses and midwives could do 
the testing at the true point of care.” n
50% 
percentage of babies born 
with HIV/AIDS in Mozambique 
who will die before their  
second birthday if left  
untreated 
16% 
percentage of Mozambican 
citizens infected with HIV/AIDS
141,582 
number of Mozambican  
children living with HIV/AIDS
14,652 
number of Mozambican  
children receiving treatment 
for HIV/AIDS
11.3% 
estimated HIV prevalence in 
children in Mozambique
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hether it’s the Gulf oil spill, 
the obesity epidemic, lead  
in children’s toys, or the 
out break of the H1N1 virus, major public health 
issues regularly capture newspaper headlines and 
the public’s attention. But for years, education in 
public health was reserved exclusively for gradu-
ate students. Today, however, it is one of the five 
most rapidly growing college majors, according 
to The Chronicle of Higher Education.
In 2003, the Institute of Medicine (IOM) of the National 
Academies recommended that all undergraduates have ac-
cess to a public health education. In 2006, the Association 
of Schools of Public Health (ASPH) agreed that undergradu-
ate public health training was necessary to develop an edu-
cated citizenry. And in 2009, the Association of American 
Colleges and Universities (AACU) found the field so timely 
that it dedicated an issue of its journal to undergraduate 
public health.
Even the federal government has hopped on board. The 
U.S. Department of Health and Human Services recently pro-
claimed support for undergraduate education in public health 
through progressive recommendations in Healthy People 2020, 
a set of science-based objectives for promoting disease preven-
tion and health in this decade. 
No one is more knowledgeable about the rapid rise of un-
dergraduate education in public health — or has had a greater 
impact on it — than Richard Riegelman, M.D., Ph.D., M.P.H., 
the founding dean of GW’s School of Public Health and  
Health Services and professor of Epidemiology and Biostatis-
tics. As co-chair of the Healthy People Curriculum Task Force, 
a chief voice of AACU’s Educated Citizen and Public Health 
Initiative, a leader in ASPH’s Undergraduate Public Health 
Learning Outcomes Project, and co-author of the foundational 
curriculum for undergraduate education in public health, 
Public Health 101 
 Richard Riegelman Lays the Foundation for a Health-Savvy Society 
Interview by Anna Miller
W
question and answer
P
H
O
T
O
G
R
A
P
H
Y
 B
Y
 H
O
L
G
E
R
 T
H
O
SS
30   GWUMC.EDU    •    W I N T E R  2 0 1 11  M E D I C I N E  +  H E A LT H        31
Riegelman is recognized as one of the movement’s key driving 
forces.
Why is it important to offer undergraduate public health education?  
The undergraduate public health degree does much more 
than prepare students to get a job in public health. Rather, it’s 
about teaching them how to understand public health issues, 
whether they become clinicians, lawyers, or business people.  
The goal is to prepare students to understand the world 
around them, the thinking process, the evidence process of 
public health. What we [the AACU] want to build is “the 
educated citizen,” someone who can incorporate public health 
concepts into his or her decision-making processes.
Why has undergraduate education in public health grown so rapidly? 
This is a student-driven movement. When I talk to people 
around the country about getting started, I tell them, “Put on 
a good global health course or a good public health course and 
the students will do the rest,” because the students will enroll, 
and they’ll want more. At GW, we have to turn away students 
in the introductory courses, and that’s been the case for many, 
many institutions. For students, this field of study is inherently 
relevant and important to our society, so it’s not a hard sell. 
How will the Healthy People 2020 goals affect undergraduate public health 
education?
There are two key objectives that will impact undergraduate 
public health education. The first is to increase the number of 
four-year colleges that offer undergraduate majors or minors. 
The second is to increase the number of two-year colleges that 
offer basic public health courses, as well as job-related certifi-
cates and associate degrees. Through those objectives we hope 
to achieve as much as a 40 percent increase in the number of 
both four-year and two-year colleges and universities. 
Why are these goals significant?
At last count, only about 16 percent of colleges and universi-
ties offered public health majors or minors. We hope that 
the Healthy People 2020 goals will enable public health to 
be seen as an important part of any higher education cur-
riculum. We hope that people will eventually see that Public 
Health 101, Epidemiology 101, and Global Health 101 are 
just as important as Economics 101, Psychology 101, and 
Political Science 101. The mentality should be, “Of course 
this is a part of undergraduate education.” 
What are you doing to help implement these goals? 
I have been working a lot on making things easier for the fac-
ulty, since one of the major challenges with the movement is 
recruiting and preparing them to teach undergraduate public 
health. When the faculty are provided with course frame-
works, learning objectives, and help on how to get the classes 
approved, they can receive the support they need to get this 
discipline to become part of their institution’s curriculum and 
academic culture.
What is GW’s role in the undergraduate public health movement?
GW’s undergraduate public health program has been 
recognized as a national model. This is because, I think, 
we have had a reasonably clear goal of what we want to 
do. Our strategy is to create a generalist program, with a 
lot of broad foundations, integrated courses, and synthesis. 
The bottom line is that we are creating something that is 
different from what is done at the graduate level, which 
tends to be more discipline-based. The undergraduate pro-
grams focus on the breadth of the field, while the graduate 
programs focus on its depth. This is an approach that is 
catching on nationally. 
We also have a commitment to teaching at GW — we don’t 
have to pull teeth to get faculty to teach undergraduate courses. 
We have people who love it, so everybody who teaches under-
graduates here does it because they want to.
How has the movement changed from when you first began advocating for 
undergraduate programs in public health?
It’s great to be involved in a project where I can really see 
changes being made. It’s very reinforcing to see the kind 
of progress being made and the kind of enthusiasm from 
students. You push uphill, but once you achieve acceptance 
from 4,000 four-year colleges, 1,100 community colleges, 
and even the federal government, all acknowledging that 
this is a good idea, it’s a different story; a different dynam-
ic. It’s no longer an uphill fight. Now it’s about guidance 
on how this whole thing should be run. n 
“We also have a commitment to 
teaching at GW — we don’t have 
to pull teeth to get people to  
teach undergraduate courses.  
We have people who love it,  
so everybody who teaches  
undergraduates here does it  
because they want to.” 
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Sunburns can lead to cancer. Colitis can lead to 
cancer. Hepatitis B and C can lead to cancer. Persis-
tent infection and inflammation may lead to cancer. 
Lead a perfectly healthy life, and you might get cancer 
nonetheless. Any number of factors trigger the disease, 
depending on your genes and the molecular cascades 
they set in motion in your body. In some people, a fac-
tor may prompt a gene that sets off cascade A, which 
causes a normal cell to turn cancerous. In others, a 
variation of that gene may trigger cascade B, which 
kills a cancerous cell before it can spread. Master con-
trol genes direct these cascades, thereby determining 
the path taken. 
One such master controller, a gene encoding a 
protein called MTA1 (metastasis-associated protein 1), 
has been found lurking in breast, ovarian, prostate, and 
other tumors. At GW’s School of Medicine and Health 
Sciences, a small army of scientists recently gathered to 
tackle the MTA1 family of proteins. They’re out to ex-
pose how and why it flips the switch to a cancerous out-
come, and what molecular middlemen it employs to do 
its dirty work. The team is led by Rakesh Kumar, Ph.D., 
professor and the Catharine Birch and William McCor-
mick Endowed Chair of the Department of Biochem-
istry and Molecular Biology. As co-author of the 2008 
book NR [nuclear receptor] Coregulators and Human 
Diseases, Kumar predicted that “Coregulator ‘master 
genes’ are poised to pay big future dividends to the field 
of medicine.” Now he and the bright young minds he’s 
recruited to his lab are betting their careers on it. 
A FORMIDABLE LINEUP
Amanda Lyon, a 26-year-old Ph.D. student at GW, 
joined the MTA1 team in January 2010. She’s research-
ing the presumed connection between hepatitis B, 
MTA1, and cancer. Recent studies suggest that bits of 
the hepatitis B virus interact with the MTA1 molecule, 
and since MTA1 is associated with cancer, Lyon will 
try to connect the dots. She’s running experiments to 
learn how MTA1 helps the virus activate molecular 
pathways that turn normal cells cancerous. In a similar 
vein, her lab-mate, postdoctoral fellow Suresh Pakala, is 
investigating whether infections trigger MTA-mediated 
cancer pathways. After a recent report by Kumar and 
his colleagues on how MTA1 orchestrates a type of 
breast cancer not caused by heritable mutations, GW’s 
Combating Cancer From  
the Top Down
  GW researchers tackle a master control gene lurking behind cancer
At top, the hepatitis B virus increases MTA1 levels 
in liver cells.  Below, MTA1 increases in irradiated 
cancer cells, helping them repair DNA damage.
By Amy Maxmen
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MTA1 team is looking into whether inflammation triggers 
MTA1 to do so. 
Deep questions posed by the MTA1 team are intended 
to get at the heart of why inflammation, diseases, and stress 
are often associated with a risk for cancer. “These are the 
questions in the back of everyone’s mind,” says Lyon. Every 
Monday, she and the team gather to share insights and trade 
secrets. In the process of exposing MTA1’s inner ring, they are 
turning this gene into the poster child for an emerging field of 
cancer research on master control genes, or coregulators, that 
govern a myriad of molecular cascades. 
 “This MTA1 program will give coregulators national 
visibility and give focus to a field that is developing in basic 
research,” says Bert O’Malley, Kumar’s colleague and a 
longtime coregulator expert at Baylor College of Medicine in 
Houston, Texas. “Frankly, right now this is one of the hot-
test fields in fundamental and translational cancer research.” 
MTA1: CALLING THE SHOTS
Like CEOs in a corporation, coregulators run the show; they 
determine which molecular pathways are turned on or off 
by interfering with genes that act like managers, which in 
turn guide a staff of genes below them. These genes encode 
proteins that eventually direct cell growth, division, metabo-
lism, and other functions. When researchers first became 
cognizant of coregulators about 15 years ago, O’Malley says, 
they were thought to simply smooth out transcription (the 
process in which DNA becomes RNA, before RNA is made 
into protein). “But in time we began to find many more of 
these than we had expected. And the big surprise is that they 
turned out to be a type of ‘master gene.’” He adds, “Now, 
we know these are big-picture molecules in the cell, which 
is why they’ve been so frequently co-opted by diseases.” In 
other words, it is more efficient to kidnap a master control 
gene than to manipulate dozens of individual genes farther 
down on the chain of command.
Of some 375 coregulators discovered since 1995, more 
than half have been linked with maladies, such as mental 
retardation, inflammatory disorders, heart and reproductive 
abnormalities, and cancer. And MTA1 has some unique prop-
erties. Unlike other coregulators, it can either activate or stifle 
a molecular pathway. Whereas some coregulators act like stop 
signs, unable to signal “go,” MTA1 flashes like a traffic light. 
Understanding what makes MTA1 signal “stop” or “go” is the 
subject of intense research among the scientists in Kumar’s lab. 
In 2001, Kumar and his colleagues turned heads with a 
paper in Nature Cell Biology, proposing a novel process by 
which MTA1 participates in hormone-independent breast 
cancer, a type resistant to standard therapies. They suggested 
that MTA1 dictates which gene cascades activate by remodel-
ing the shape of chromatin, the material in which genes are 
embedded. When chromatin is in one shape, certain DNA 
sequences are transcribed into RNA, which is translated into 
a protein that triggers a cascade. But when chromatin takes 
on another shape, that DNA sequence is blocked and can no 
longer be transcribed. The report proposed a basic model for 
how MTA1 manipulates pathways by remodeling chromatin, 
but the fine details remain elusive. That’s where Sujit Nair, 
Ph.D., comes in.
Nair was struck by the wonders of chromatin remodeling 
back in 2004 as a postdoctoral fellow in Kumar’s labora-
tory at MD Anderson Cancer Center in Houston. Now he’s 
come to GW to join the MTA1 team and work as an assistant 
research professor in the Department of Biochemistry and 
Molecular Biology. He’s focusing on MTA1 and chromatin 
remodeling, and the effect that these rearrangements have on 
genes downstream.  
HUNTING FOR A CURE 
Because MTA1 has stuck its fingers into so many crannies, 
blocking the molecule with a drug might have unintended 
consequences. That’s one of the reasons MTA1 research is so 
important, says Jeyanthy Eswaran, Ph.D., assistant research 
professor and director of the McCormick Genomics and 
Proteomic Center at GW. Eswaran, who is the most recent 
recruit to the Kumar lab, says pinpointing genes involved 
in the many cancer-causing cascades that MTA1 halts or 
launches might inspire drug developers. She plans to explore 
the genes and proteins that are expressed in human cancer 
patients bearing high levels of MTA1. If one or more of 
these proteins is higher or lower than usual 
when MTA1 is turned up, it could provide a 
promising target for a cancer drug. “There 
haven’t been any radical new drugs for a 
while, so we are looking for new targets 
with unique qualities,” she explains. “MTA1 could very well 
be the critical player.”
Last year, the team stumbled on another MTA1 function 
likely to pique the interest of drug developers. When cancer 
patients undergo radiation therapy, the goal is to slow cancer 
by damaging the DNA in cancerous cells. But cancer fights 
back by turning up the cells’ DNA repair pathways, mitigat-
ing damage caused by the treatments. MTA1 may govern 
at least one pathway that comes to the aid of cancer cells. 
Therefore, drugs modifying MTA1 might make DNA- 
damaging therapy more effective. 
“Collectively, I know we’ll make progress,” Eswaran 
adds. “All of us hope to see our projects lead to the clinic, 
where the patients are. That’s the bottom line.” n
Drugs modifying MTA1 might make DNA-damaging therapy 
more effective for cancer patients in the future. 
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GW Chair of Surgery Joseph Giordano 
Closes Academic Career
After training generations of young surgeons and setting the standard 
for GW surgical residency as head of the program for more than 18 
years, Joseph Giordano, M.D., chair of GW’s Department of Surgery, 
announced his retirement in June, bringing to a close a distinguished 
42-year academic career. 
During Giordano’s tenure at the Medical Center, the depart-
ment emphasized inpatient and outpatient care, technical skills, and 
research training to produce clinically talented surgeons who have 
high academic potential. Giordano also was instrumental in estab-
lishing GW Hospital as a Level I trauma center, which treats nearly 
70,000 patients each year. 
But it was his role as head of the trauma team that treated Presi-
dent Ronald Reagan, along with Press Secretary James Brady, 
Secret Service Agent Tim McCarthy, and D.C. police officer Thomas 
Delahanty, following John Hinckley’s 1981 assassination attempt that 
thrust Giordano into the national spotlight.
Giordano discovered a bullet was lodged just inches from the 
president’s heart, inserted a chest tube, and brought his blood pres-
sure back to normal. The president was famously quoted remarking 
to the surgeons, “I hope you’re all Republicans!” To which Giordano 
replied, “Today, Mr. President, we’re all Republicans.”
Far from taking it easy in his retirement, Giordano will devote his 
time to his work with Partner for Surgery, a non-profit organization 
that provides surgical care in remote Guatemalan communities.
During a press conference following the 1981 assassination attempt on President Ronald 
Reagan, Joseph Giordano, M.D. (left) and Benjamin Aaron, M.D., then chief of 
Cardiothoracic Surgery, demonstrated the location and extent of the president’s injuries.
FACULTY NEWS
Plack Selected as Interim Head 
of Health Sciences
Margaret Plack, P.T., Ed.D., chair of the Depart-
ment of Health Care Sciences and founder 
and director of the Doctor in Physical Therapy 
program at the School of Medicine and Health 
Sciences, was appointed to serve as the interim 
senior associate dean for Health Sciences. 
Plack fills the position most recently held by 
Jean Johnson, Ph.D., F.A.A.N., who became the 
inaugural dean of GW’s new School of Nursing.
Plack has 25 years of experience in both 
academics and clinical practice, and specializes 
in physical therapy for children with developmen-
tal disabilities. 
Parkin Receives Public Health 
Award 
The Association of Schools of Public Health 
(ASPH) recently selected Rebecca Parkin, Ph.D., 
M.P.H., former associate dean for Research  
and Public Health Practice and professor of 
Environmental and Occupational Health and of 
Epidemiology and Biostatistics in GW’s School 
of Public Health and Health Services, to receive 
its 2010 ASPH/Pfizer Faculty Award for Excel-
lence in Academic Public Health Practice. 
Parkin, who recently retired after 12 years of ser-
vice at SPHHS, was honored for her renowned 
practice-oriented scholarship and service in 
environmental epidemiology and risk science.  
GW Surgical Team Brings Cardiac 
Care to Rural Honduras
A team of health professionals from The Richard 
B. and Lynne V. Cheney Cardiovascular Institute 
at GW Medical Center recently participated in a 
medical mission to rural Honduras. Cindy Tracy, 
M.D., associate director, Division of Cardiology 
at the Medical Center, along with cardiology 
fellow Monica Mukherjee, M.D., and technicians 
from GW’s Cardiac Catheterization lab provided 
desperately needed cardiac devices, such as 
pacemakers and defibrillators, to an under-
served population. They also performed surgical 
procedures on 19 patients suffering from life-
threatening heart disease.
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CLASS NOTES
1950s
GEORGE F. SNELL, M.D. ’58, a retired 
physician in Kaysville, Utah, was  
honored as Kaysville’s Unsung Hero 
in July 2010 for his dedication to the 
area’s medical community. 
1970s
JUD KNOX, M.H.A. ’72, chief executive 
officer of York Hospital, was selected as 
chair of the Maine Hospital Association 
Board of Directors in June 2010.
MAS G. MASSOUMI, M.D., G.M.E. ’73, an 
orthopedic surgeon, became a lifetime 
member of the American Society for 
Surgery of the Hand in October 2010. 
He also was a guest lecturer at the 11th 
Triennial Congress of the International 
Federation of Societies for Surgery of 
the Hand, held in Seoul, South Korea, 
in November 2010.
OMEGA C. LOGAN SILVA, M.D., G.M.E. ’75, 
M.A.C.P., was awarded the Foremother 
Award of the National Research Center 
for Women and Families in May 2010. 
1980s
DAVID B. DOMAN, M.D., G.M.E. ’81, clinical 
professor of Medicine at The George 
Washington University, was appointed 
to the editorial board of the peer- 
reviewed journal Gastroenterology 
and Hepatology.
RICARDO EUSEBIO, M.D. ’81, F.A.C.S., was 
appointed associate administrator of 
medical services for Guam Memorial 
Hospital Authority. 
HOWARD ZUCKER, M.D. ’82, J.D., L.L.M., 
an anesthesiologist and pediatrician, 
volunteered in Sacre Coeur Hospital in 
Milot, Haiti, for a week in April 2010 
following the devastating earthquake 
that struck the nation. 
DAVID P. SNIEZEK, M.D., G.M.E. ’83,  
director of the Advanced Integrative 
Rehabilitation and Pain Center in 
Washington, D.C., joined a medical 
relief mission in Haiti for nine days in 
May 2010.
ERICH P. JUNGER, B.S. ’87, PH.D., a U.S. 
Customs and Border Protection scien-
tist, was featured in April in the Investi-
gation Discovery Channel series Solved: 
Extreme Forensics, for his role in aiding 
the Warren County Sheriff’s Office in 
solving the murder of a Virginia man.
1990s
PHILEMON BAILEY, B.S. ’92, M.D., a board-
certified emergency physician with  
Sussex Emergency Associates at Beebe 
Medical Center in Lewes, Del., received 
the EMS Physician of the Year award. 
DAYNA L. WOLFE, M.D. ’95, a neuromodu-
lation senior clinical research specialist 
and clinical advisor with Medtronic, Inc., 
the lead physician with the Minnesota 
State Medical Review Team, and a con-
sultant to the Minnesota Department of 
Human Services’ Health Policy Unit, was 
appointed in March 2010 to the State 
Rehabilitation Council in Minnesota.
2000s
JOHN TROTTER II, M.D. ’02, was appoint-
ed as chief medical officer of XYTOS, 
Inc., a Nevada-based biomedical tech-
nologies company, in May 2010. 
JASKARAN BOPARAI, B.S. ’08, was 
appointed clinical project manager at 
ACR Image Metrix, an imaging contract 
research organization, in July 2010. 
CINDY LENTINO, M.S. ’09, was referenced 
in numerous publications, including 
Men’s Health, Shape, and Medical 
News Today, for her study “Dog-
walking is Associated with a Favorable 
Risk Profile in Middle-age,” originally 
published in the journal Medicine and 
Science in Sports and Exercise, May 
2010. Lentino presented her findings at 
the American College of Sports Medi-
cine’s annual meeting June 1–5, 2010, 
in Baltimore, Md.
Bernard Bouscarel, Ph.D., D.Sc., 
professor of Biochemistry and Molecu-
lar Biology and of Medicine, director of 
the Digestive Diseases Center, director 
of the Molecular Medicine program, 
and chair of the Basic Science faculty, 
died on May 30, 2010, at age 53. 
Bouscarel, known as “the Frenchman” 
on campus, decorated even the dens-
est of Gastroenterology lectures with 
his accented speech. But he offered 
much more to those around him than 
European charm. A renowned scientist, 
an admired professor, and an adoring 
husband and father, Bouscarel was a 
wealth of wisdom, generosity, humor, 
and graciousness. 
He had been a member of the GW 
Medical Center community since 
1988, conducted leading research in 
liver disease and anticancer agents 
and their side effects, and published 
more than 60 articles in some of the 
most prestigious journals in the field. 
Bouscarel was a mentor to numerous 
students and the husband of Susan 
Ceryak, Ph.D., associate research  
professor of Pharmacology and  
Physiology at GW.
Stanley Greenspan, M.D., Ph.D.,  
clinical professor of Psychiatry and 
Behavioral Sciences, died April 27, 
2010, of complications from a stroke. 
He was 68. The author of numerous 
books on child behavior, including 
The Challenging Child, First Feelings, 
The Essential Partnership, and Play-
ground Politics, Greenspan is most re-
membered for his “Floortime” method 
of addressing the social and emotional 
deficits of children with autism.
In Memoriam
alumni
BRUCE BENNETT, M.D. ’38
THOMAS M. DAVIS JR., M.D. ’52
CARL J. HOFFMAN, M.D. ’45
CARL MACCARTEE JR., M.D., G.M.E. ’72
HAROLD ELLIS RHAME JR., M.D. ’50
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“Your residency teaches you how to practice medicine, but 
it doesn’t teach you how to build the system. My fellowship at 
GW taught me how to build the system,” he says, citing training 
in hospital administration, finance, management, economics, 
public health, and health policy, among other disciplines. 
Mulligan’s public health training, he says, complemented 
his fellowship by teaching him how to “think on the right 
scale” in a multifaceted field. “If you don’t have public health 
training, your thinking is usually too small in terms of medi-
cal development,” he says. 
In 2003, Mulligan joined a team from GW who helped to 
establish Emergency Medicine residencies in Iran, Chile, and 
India; start a paramedic training school in Oman; begin an 
emergency nursing training school in Kuwait; and implement 
ambulance and disaster training in the United Arab Emirates. 
Mulligan moved to the Netherlands in 2006 to help cre-
ate one of the nation’s first emergency medicine residencies 
at Erasmus University in Rotterdam. He has since helped 
develop a similar program at UMC Utrecht, another of the 
country’s eight medical schools. Over the last 10 years,  
Mulligan has initiated and participated in international 
emergency medicine development programs in more than two 
dozen countries and assisted in establishing training schools 
for paramedics, relief agencies for underserved areas, disaster 
medicine and preparation programs, and hospital trauma 
development systems in more than 20 countries.
Among other international leadership roles in emergency 
medicine, Mulligan currently acts as co-director of the 
Emergency Medicine Residency at UMC Utrecht and clinical 
assistant professor in the Department of Emergency Medi-
cine at the University of Maryland School of Medicine. 
“The things that are killing health care systems around the 
world are emergency problems related to non-communicable 
diseases such as cardiovascular disease, strokes, cancer, and 
trauma, yet most of the world doesn’t have the capacity to 
handle them,” says Mulligan. “So, to me, helping countries 
develop systems for emergency care is the way I can make the 
greatest public health impact.” n
Terrence Mulligan
BUILDING EMERGENCY MEDICINE SYSTEMS AROUND  
THE WORLD
Mulligan’s public health training  
complemented his fellowship by teaching  
him how to “think on the right scale.”  
“If you don’t have public health training, 
your thinking is usually too small in terms  
of medical development.”
Accident-prone travelers take note: “If you get hit by a moped 
in a country like the Netherlands, you will most likely be 
taken care of by a first-year doctor — one who has not had 
any specialized training in emergency medicine,” says Ter-
rence Mulligan, D.O., M.P.H. ’03. “Outside of the United 
States, a fully developed emergency medicine system is hard 
to find, even in otherwise well-developed countries.” 
Though few ever stop to consider it, an emergency 
medicine system is dizzyingly complex. From ambulance 
networks, to emergency room administration, to specialty 
training, the system involves many interacting components 
that must be built in the countries where they are lacking. 
Thanks to GW — where he simultaneously achieved an 
M.P.H. and became the Medical Center’s first International 
Emergency Medicine Fellow — Mulligan is helping to create 
these systems, one country at a time. 
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Making an Impact
FROM COMMUNITY TRAINING TO COLON CANCER  
RESEARCH, GW STUDENT INITIATIVES WORK TOWARD A  
HEALTHIER WORLD
SARAH DIAMOND, M.P.H. CANDIDATE 2012, GLOBAL HEALTH
A school of public health seems an unlikely home for a 
chapter of Engineers Without Borders (EWB), an organiza-
tion promoting sustainable engineering projects in developing 
countries. But for Sarah Diamond, a second-year M.P.H. 
candidate in the School of Public Health and Health Services 
(SPHHS), the two are a perfect fit. 
“Many of the engineering projects taking place around 
the world have substantial public health implications,” argues 
Diamond, president of EWB, the only chapter based in a 
public health school. 
For the past 10 months, Diamond has been developing a 
community health manual for a project in El Salvador, where 
engineers are building a new water system. “The engineers 
design and construct this great system, but if the community 
has never had water piped before, they need to learn how to 
use it,” she says.
For someone with such zeal for public health, Diamond is 
a relative newcomer to the field. While pursuing her master’s 
degree in flute performance at Ohio University, Diamond fell 
under the influence of friends pursuing fields such as inter-
national development. “There was a 
whole world out there that I had no idea 
about,” recalls the classically trained 
musician. “I spent hours a day in a tiny 
room practicing my flute. What differ-
ence was I making?” 
To get a sense of what she was miss-
ing, Diamond volunteered on a public 
health mission to Ecuador and fell in 
love with the experience. “I came back 
from that trip thinking, ‘Music isn’t the 
career for me. What am I going to do 
now?’” she explains.  
Diamond was soon swept into a 
whirlwind of experiences that began 
during a stint as an AmeriCorps volun-
teer and ended in Washington, D.C., 
where she is now studying in the Global 
Health program. 
“I believe you go after what’s 
important to you,” explains Diamond. 
“And that’s exactly what I’m doing.” 
CARRIE HOUSE, PH.D. CANDIDATE 2011, MOLECULAR MEDICINE
For Carrie House, a fifth-year doctoral candidate in the 
School of Medicine and Health Sciences’ Molecular Medi-
cine program, basic science represents an irresistible lure to 
uncover the mechanisms lurking behind disease.
Under the guidance of Norman Lee, Ph.D., professor of 
Pharmacology and Physiology, House is exploring the role that 
voltage-activated sodium channels play in colon cancer. By 
employing a variety of pharmacological tools, she is evaluating 
how changes in the cells give them an oncogenic advantage.
“This project is so fitting for molecular medicine,” says 
House. The research corresponds neatly with the program’s 
three tracks: molecular and cellular oncology, neuroscience, 
and pharmacology. 
The project, which has served as the center of House’s 
professional life for nearly four years, grew out of a sequenc-
ing study in Lee’s lab involving mutations in voltage-activated 
sodium channels — channels already implicated in breast, 
prostate, and lung cancers. 
House has managed to use her study requirements to 
advance not only her education, but also the project itself, 
successfully parlaying a writing grant assignment into funds 
for her research. “I figured, if I have to write a grant proposal, 
I may as well submit it,” she recalls. “I thought it was a good 
idea.” Clearly, the PhRMA Foundation thought so, too, and 
awarded House a $40,000 grant over two years. n
From left, Carrie House and Sarah Diamond take charge of their education.
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The inaugural class of GW’s Bachelor of Science in Nursing students 
has a lot to celebrate. At a traditional pinning ceremony on Dec. 6, 2010, members of the class 
commemorated both the completion of their program and their passage into a health care 
workforce that needs their skills now more than ever. Though they began their studies in the 
School of Medicine and Health Sciences’ Department of Nursing Education, they graduated as 
alumni of the newly established GW School of Nursing.
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